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Bone marrow is a target organ site involved in multiple diseases
including myeloproliferative disorders and hematologic malignancies and
metastases from breast and prostate. Most of these diseases are characterized
with poor quality of life, and the treatment options are not very specific due to
lack of delivery mechanisms which results in dose limitation to protect the
healthy hematopoietic cells. Therefore, there is a critical need to develop
effective therapeutic strategies that allow for selective delivery of therapeutic
payload to the bone marrow. Nanotechnology-based drug delivery systems
provide the opportunity to deliver drugs to the target tissue while decreasing
exposure to normal tissues. E-selectin is constitutively expressed on the bone
marrow vasculature, but almost absent in normal vessels, and therefore, Eselectin targeted drug delivery presents an ideal strategy for the delivery of
therapeutic nanoparticles to the bone marrow.
The objective of this study was to develop a novel bone marrow targeted
multistage vector (MSV) via E-selectin for delivery of therapeutics and imaging
agents. To achieve this goal, Firstly, an E-selectin thioaptamer (ESTA) ligand
was identified through a two-step screening from a combinatorial thioaptamer
library. Next, ESTA-conjugated MSV (ESTA-MSV) were developed and
evaluated for their stability and binding to E-selectin expressing endothelial cells.
#!
!

Different types of nanoparticles including liposomes, quantum dots, and iron
oxide nanoparticles were loaded into the porous structure of ESTA-MSV. In vivo
targeting experiments demonstrated 8-fold higher accumulation of ESTA-MSV in
the mouse bone marrow as compared to non-targeted MSV Furthermore,
intravenous injection of liposomes loaded ESTA-MSV resulted in a significantly
higher accumulation of liposome in the bone marrow space as compared to
injection of non-targeted MSV or liposomes alone. Overall this study provides
first evidence that E-selectin targeted multistage vector preferentially targets to
bone marrow vasculature and delivers larger amounts of nanoparticles. This
delivery strategy holds potential for the selective delivery of large amounts of
therapeutic payload to the vascular niches in the bone marrow for the treatment
of bone marrow associated diseases.
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Chapter 1. Introduction
1.1 Bone marrow
1.1.1 Composition, function and structure
The bone marrow (BM) is a loose connective tissue within the central
cavities of the bones of the body. BM is a richly cellular and a highly vascular
organ and one of the largest organs in the body. BM is the major hematopoietic
organ and a primary lymphoid tissue that is responsible for the production of
hematopoietic cells. The cellular composition of BM consists of
1. Precursor and mature blood cells
•

Hematopoietic stem cells and precursor blood cells

•

Blood cells - erythrocytes, leukocytes, granulocytes, lymphocytes
and platelets

2. Stromal cells
•

Osteoclasts

•

Osteoblasts

•

Endothelial cells

•

Fibroblasts

•

Adipocytes

•

Macrophages

The cellularity and vascularity of BM can change rapidly in response to
various physiological and pathological stimuli. In addition to its prime
hematopoietic activity, bone marrow has distinct phagocytic and endocytic
function due to the presence of macrophages and endothelial cells delineating its
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sinuses, respectively. However, deeper understanding of the anatomical and
physiological characteristics of the bone marrow is a prerequisite for achieving
efficient delivery of therapeutics to the bone marrow.

1.1.2 Anatomical properties of the bone marrow
The foremost characteristic of bone marrow organization is its vascular
arrangement. The bone marrow is divided into wedge-shaped hematopoietic
compartments filled with proliferating and differentiating blood cells in connective
tissue matrices bordered by specialized vascular structure known as venous
sinuses (1). The vascular system of marrow consists of venous sinuses, veins,
and arteries. The major arterial supply of the BM in a long tubular bone is the
nutrient artery that runs in the central longitudinal axis. The marrow does not
have any lymphatics. The vascular arrangement provides a high number of small
vessels and sinuses at the periphery of the bones, and, as a result,
hematopoiesis is most active at these peripheries. The sinus wall forms a barrier
between the hematopoietic compartment and the circulation and has three
distinct components.

1. Endothelial cells that form the inner layer
2. Adventital cells that form the outer discontinuous layer
3. A discontinuous basal lamina

&!
!

Figure 1. Vascular architecture of the bone marrow. Presence of extensively
distributed microvessels comprising of venous sinuses is characteristic of BM.
The major arterial supply is the nutrient artery that runs in the central longitudinal
axis.
Reproduced by per mission from Toxicologic Pathology, Travlos G. 2006 (1),
copyright Society of Toxicologic Pathology (2006).
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1.1.3 Physiological properties of the bone marrow
Changes in the blood flow on both a volume and velocity basis have been
shown to influence the delivery of drug carriers to any specific site. Due to a
variation in the content of the red marrow, there is a considerable variation in the
amount of blood flowing through the marrow (2). The blood flow in the marrow
can also be altered experimentally by treating animals with phenylhydrazine or
acetylcholine (3). However, it has been noted that the average hydrodynamic
shear in BM micro vessels is lower than in most other organs (4) to maximize the
exchange and transport of cells across the hematopoietic spaces. This property
of lower shear rates can be an advantageous in selective delivery of drug
carriers to the BM.

1.1.4 Bone marrow associated diseases
Based on the given importance of this organ, damage to the
hematopoietic and/or phagocytic components of this multifunctional organ can
negatively impact the physiology of the body.
1. For example, a number of pathogenic microorganisms, such as
Mycobacterium bacilli, Brucellosis, etc., can invade bone marrow and can
cause undesirable effects such as anemia, leukopenia and chronic
infections (5).
2. Bone is one of the most common sites of metastasis originating from
primary tumors from the breast or prostate causing severe bone pain,
pathological fractures, spinal cord compression and hypercalcemia (6).
Bone metastasis frequently occurs in metastatic breast cancer patients
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(60 to 80 %) and is associated with poor prognosis (5 year survival rate <
20%) and low quality of life (6).
3. Myeloproliferative disorders for e.g. chronic myelogenous leukemia (CML)
characterized by an overproduction of one or more types precursor cells
originating in the BM (7).
4. Immune deficiency disorders are associated with a loss of precursor cells
in the BM (8).
5. Multiple myeloma characterized as the cancer of the plasma cells
originates in the BM (9),
6. Lastly, a large number of anti-neoplastic drugs and therapeutic agents that
lack cell specific recognition result in bone marrow toxicity such as
myelosuppression (10). This results in maximum tolerated dose (MTD)
based therapy, which is less effective against diseases such as cancer.

1.1.5 Treatment of BM associated diseases
Current treatment options for BM diseases associated are limited and
consist of either cytotoxic chemotherapy or bone marrow transplantation.
Chemotherapy is dose limited due to toxic effects on healthy cells and
unfortunately,

only

about

30

percent

of

patients

are

candidates

for

transplantation because of age limitations or lack of a suitable HLA-matched
donor [7]. These facts collectively highlight an urgent need for effective delivery
of therapeutic agents for the treatment of diseases of the bone marrow and for
the protection and stimulation of the inherent physiological function of this organ.
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The ability of the bone marrow to uptake particulates from the
bloodstream has opened up an opportunity for delivery of therapeutic agents
efficiently by means of drug delivery carriers. In conjunction with the
physiological and anatomical characteristics of the bone marrow, two types of
BM targeting strategies have been developed. Porter et al., showed a passive
targeting approach in which microspheres coated with a copolymer evaded liver
and spleen uptake and accumulated in the BM (11). This occurred mainly due to
the highly branched and sinusoidal nature of the BM vasculature and the
phagocytic uptake. Recently, a targeted therapy using humanized monoclonal
antibody against RANK ligand (Denosumab) was approved by the FDA for
treatment of osteoporosis and bone metastases (12, 13). Denosumab inhibits the
RANK ligand interaction with RANK receptor on precursor osteoclasts, and
blocks the osteoclast maturation, and inhibits bone resoprtion a pathological
condition during bone metastases. Targeted therapy comprising of this
humanized antibody is extremely expensive (14) and such forms of targeting
suffer from limitations in terms of their specificity to the BM organ leading to low
overall accumulation in the organ. Therefore, a novel strategy for the delivery of
drugs to the BM is needed for further enhancing their therapeutic efficacy.

1.2 Nanotechnology
In 1959, Nobel Laureate Richard Feynman gave his famous lecture titled
“There’s plenty of room at the bottom” prompting the research community to
visualize things at the sub-atomic scale. The culmination of his vision occurred
through the field of nanotechnology, which refers to the design, characterization,
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and application of systems in the nanoscale range (1-100 nm). For any device to
be considered nanotechnological, it has to be man-made comprising of crucial
components in the nanoscale range (15). Additionally, it is equally necessary
that the device possess novel properties that emerge due to its nanoscale
dimension. These properties could include mechanical, thermal, electrical,
magnetic, and optical properties. Nanoparticles, for example, take the advantage
of their dramatically increased surface area to volume ratio. For perspective,
nanoscale is comparable in dimensions to the interatomic distances in crystalline
lattices and is illustrated with respect to other familiar things in figure 2.

Although the full potential of nanotechnology is just beginning to be realized, the
following fields have been impacted by nanotechnology
1. Information and communication
2. Medicine
3. Chemistry and environment
4. Energy
5. Consumer goods

Figure 2. Nanoscale size range relative to other familiar objects. The
nanoscale ranges between 1-100 nm. Nanoscale devices are smaller than
human cells and are similar in size to biological macromolecules such as
enzymes, viruses etc. Some commonly used nanotechnology based platforms
existing in this range are also presented here.
Reproduced with permission from Journal of Leukocyte Biology, McNeil S, 2005.
(16), Copyright Society for Leukocyte Biology (2005).
+!
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1.2.1 Nanomedicine
The application of nanotechnology in the field of medicine is termed as
nanomedicine. Nanomedicine is an emerging field that offers extraordinary and
far-reaching implications for the biomedical applications such as detection,
diagnosis and treatment of critical medical conditions including cancer (17),
cardiovascular diseases (18), tissue repair (19), and for the improvement of
human health (20). The limitless possibilities offered by nanomedicine could
possibly open the door for the personalization of medicine for improved patient
outcomes (21).
For commonly used medications, multiple different routes are used
including topical, local and systemic administration. While systemic delivery such
as oral and intravenous routes of administration is the most common, each has
serious disadvantages where an effective concentration larger than clinical dose
is often required due to rapid clearance of the drug and lack of targeting. For this
reason, the maximum effectiveness of the drug is limited. Any injected
therapeutic agent encounters multiple obstacles termed as bio-barriers that
adversely impact its ability to reach the intended destination at the desired
concentration (22). These bio-barriers include physiological barriers such as
epithelial/endothelial membranes, reticulo-endothelial system and biophysical
barriers such as interstitial pressure gradients, and transport across extracellular
matrix. For instance in cancer, one of the major issues surrounding the
chemotherapeutic treatment of solid tumors is the bioavailability of the drug at
the tumor site. When quantified the drug concentration in a tumor corresponds to
only 0.001% of the injected dose, permitting the overwhelming majority of the
drug to be systemically dispersed leading to deleterious effects (23).
-!
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Nanomedicine holds promise in the development of clinically applicable and
biocompatible materials for accurate delivery of therapeutics and imaging tracers
by negotiating these biological barriers (24). Nanotechnology based drug
delivery systems promise to expand the therapeutic window of drugs by
increasing delivery to the target tissue and decreasing drug exposure to normal
tissues (17). Some of the established nanoparticle platforms for nanomedicine
are represented in figure 2.

1.2.2 Passive vs. Active Targeting
Nanotechnology based therapeutics currently approved by the FDA are
either topical, local, or systemic application based on passive targeting
mechanism. The progress of clinical translation of novel nano-delivery methods
has been rather slow as evidenced by only a few nanoparticles that have
obtained FDA approval in the past few decades (Doxil®, AbraxaneTM). The first
generation nanoparticle drug, Doxil is a liposomal formulation of doxorubicin,
which leads to improved drug accumulation in the tumors through passive
targeting. Similarly, albumin bound paclitaxel formulation also termed as
Abraxane has shown drastic improvement in therapeutic efficacy due to
improved solubility over Taxol injection. Passive targeting relies on the enhanced
permeation and retention (EPR) effect through fenestrations for diffusion into the
diseased tissue (25). Due to the changes in the microenvironment in the
diseased tissue, the permeability of the vasculature is enhanced due to the
presence of sinusoids or fenestrations (Fig. 3). Since nanoparticles such as
Doxil are smaller in size than the size of these fenestrations, they can
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extravasate into the diseased tissue leading to increased accumulation.
However, the limitation of passive delivery strategy is that size and location of
fenestration and sinusoids are not very specific to the diseased tissue and may
result in significant non-specific uptake of circulating nanoparticles in healthy
organs. Thus, an active area of research involves functionalization of
nanoparticles with targeting moieties that identify and bind to receptors
overexpressed on or around the diseased sites, consequently maximizing
localization and accumulation in the disease area (Figure 3) (17). This secondgeneration of nanoparticles based on active targeting through biological
recognition of specific antigens on the surface of diseased cells promises to
further improve the therapeutic efficacy by enhancing the retention of
nanoparticles within the diseased site while minimizing side effects associated
with a potential off targeting (Fig. 3). Nevertheless these delivery strategies still
primarily rely on extravasation of delivery carriers from discontinuous vessels
where the size of openings varies depending on the stage of the disease and
location of the tumor (26). Furthermore, high interstitial pressure in the tumor
reduces the probability of extravasation of nanoparticles from the vessel into the
tumor tissue. Thus, developing novel drug delivery strategies that are
independent of vasculature leakiness has been an area of active research.
In this regard, vasculature is attractive target for delivery of therapeutic
and imaging contrast agents (27). For example in the case of cancer or
inflammation, the vasculature undergoes significant phenotypic changes in
response to inflammatory and/or angiogenic stimuli during carcinogenesis. This
is evident based on the presence of specific endothelial markers such as cellular
adhesion molecules, including E-selectin (28), ICAM (29), integrin avb5 (30-32),
%%!
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and VEGFR-2 (33) expression is elevated on the surface of the endothelial cells.
This significant difference in expression of surface receptor proteins between
normal and tumor endothelium make tumor associated vasculature an attractive
target for drug delivery and provide an excellent rationale for therapeutic
exploitation (34, 35).

%&!
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Figure 3. Different targeting strategies employed for drug delivery. Passive
(left), active (middle) and active vascular targeting (right). During passive
targeting the nanoparticles (NPs) extravasate through the permeable openings
in the tumor endothelium. This process can be further improved by active
targeting of the NPs to receptors on the tumor cells. In active vascular targeting,
nanoparticles favor binding to receptors overexpressed on tumor endothelium,
enhancing their accumulation in tumor tissue.
Adapted with permission from ACS Nano, Farokhzad et al, 2009 (25). Copyright
American Chemical Society (2009).
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Having introduced the first two generations of nanoparticles, it is clear that
their ability to negotiate biological barriers and carry drug payload to the desired
sites offers multiple therapeutic advantages. However, to add further
functionality and another dimension of manipulation to these existing carriers, a
third generation of nanocarrier comprising of multiple components is presented
here that has the potential to revolutionize the delivery of therapeutics by
distributing the tasks of bio-barrier avoidance, targeting, and therapeutic effect
among different stages.

1.2.3 Multistage Drug Delivery
Our laboratory has recently developed a novel multistage drug delivery
strategy, capable of multiple functions such as navigating biological barriers
encountered by nanoparticles and maximizing site-specific localization and
release of therapeutics therein. This platform comprises of nanoporous silicon
particles that can be loaded with different payload of nanoparticles including
therapeutic and imaging agents (36). The rationale for this approach is that
MSVs shoulder the burden of efficiently transporting, shielding, and controlling
the rate of release of the nanoparticle payload. A schematic describing this
concept is presented in Fig.4.
MSVs are fabricated using well-established lithographic techniques for a
precise control of shape, size, and porosity (37, 38). The outer dimension of the
MSVs can be altered from 500 nm to 20 µm in size with different shapes and the
mean pore size ranges from 5 nm to 80 nm, and the porosity ranges from 40%
to 80% (36, 37) (Fig. 5).
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Figure 4. Three generation of nanovectors. First generation of nanovectors is
based on passive targeting (top). Second generation comprises of active
targeting through biological recognition of targets (middle). Third generation
consists of multifunctional delivery systems that comprises of different
components such as the MSV (bottom). Reproduced with permission from
Pharmacological Research, Sakamoto et al, 2010 [6], copyright Elsevier (2010).
!
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Figure 5. Different types of MSVs. SEM images of different shapes of MSVs
(A-D) and different porous characteristics (E-H). List of different geometries
possible to microfabricate (table)

Shape

Dimension

Volume
µm^3

Hemispherical

Outer Diameter
3 um
2.1 um
1.6 um
1.0 um

5.0
1.5
0.80
0.17

Disk

Diameter x Thickness
3 x 0.71 um
2 x 0.36 um
1.5 x 0.45 um
0.7 x 0.44 um

5.0
1.5
0.80
0.17

Cylindrical

Diameter x Height
1.5 x 2.8 um
1 x 1.9 um
1 x 1 um
0.7x 0.44 um

5.0
1.5
0.79
0.17

Rod

Length x Width x Height
=
2.2 x 1.5 x 1.5 um
1.5 x 1 x 1 um
1.2 x 1 x 0.67 um
0.7 x 0.7 x 0.35 um

5.0
1.5
0.80
0.17
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1.2.3.1 Rational Design of MSVs
From a mathematical point of view, the vascular ‘journey’ of any
systemically injected particle can be broken down into three events: (i)
margination dynamics, (ii) firm adhesion and (iii) control of internalization.
Margination dynamics is the drifting of nanovectors towards the blood vessel
walls. Firm adhesion is the ability of a nanovector to recognize a vascular
biological target and attach firmly at the blood vessels withstanding the
hydrodynamic forces and endocytosis is referred to the ability of an adherent
nanovector to control cellular uptake (Fig. 6).
Combining together in silico mathematical modeling with in vitro and in
vivo experimental validation, the MSVs have been designed to possess the
geometry to enhance the probability for margination and adhesion to the
vascular endothelium and subsequent cellular uptake. Using a parallel plate flow
chamber under controlled hydrodynamic conditions, particles of different shapes
were analyzed and the non-spherically shaped particles drifted laterally within
the blood flow, thus increasing the probability of interacting with the blood vessel
walls, and facilitating the search for specific vascular targets as compared to
spherical particles (39, 40). Furthermore, oblate spherical particles that resemble
platelets in terms of their geometry showed firm adherence to the vessel wall
under flow conditions as compared to spherical particles for the same number of
ligand-receptor bonds (41). And lastly, the rate of internalization of particles by
cells can be adjusted by controlling the aspect ratio of the particle, as nonspherical particles resist internalization to a greater extent than spherical
particles (42). Therefore, depending on the biological properties of the target
tissue, a nanoparticle can be selected to have the geometrical and physical
%,!
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properties to optimize adhesion and cellular uptake or a combination thereof
(43).
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Figure 6. Steps in the vascular journey of a circulating particle. Margination
dynamics is the drifting of nanovectors towards the blood vessel walls. Firm
adhesion is the ability of a nanovector to recognize a vascular biological target
and attach firmly at the blood vessels withstanding the hydrodynamic forces.
Endocytosis is referred to the ability of an adherent nanovector to control cellular
uptake.
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1.2.3.2 Loading of nanoparticles into MSVs
MSVs can be loaded with various types of nanovector construct within the
approximate diameter range of 5–100 nm. Depending on the pore size, different
types and amount of nanoparticles can be loaded including labeled
nanoliposomes, gold nanoparticles, iron oxide nanoparticles, Quantum dots (Qdot) and carbon nanotubes (SWNTs) (36) (Fig. 7). Once a nanoparticle payload
is incorporated into the porous structure of the MSVs, factors governing the
release of nanoparticles include MSV degradation rates, polymeric coating, and
nanoparticle design strategies (e.g., environmentally sensitive cross-linking
techniques with pH, temperature, and/or enzymatic triggers). In addition, the
surface of the MSV can be chemically modified with different functional groups,
which allows for subsequent bioconjugation of ligand molecules for a sitespecific release of the payload for a desirable period.
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Figure 7. Loading of nanoparticles into MSV. Bright field confocal microscopy
of a single MSV (A). Confocal image showing MSV loaded with single walled
nanotubes (green) (B), Quantum-dots (red) (C) and double loading (D). SEM
image of MSV, green and red arrows show the spatial distribution of
fluorescence (E).
Reproduced with permission from Nature Nanotechnology, Tasciotti et al, 2008
(36). Copyright Nature Publishing Group (2008).
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1.2.3.3 Biodegradation of MSVs
Silicon is an attractive material in drug delivery because silicon degrades
into harmless silicic acid, which is abundant in nature. The degradation kinetics
of MSV is influenced by the porosity of the silicon particles. MSVs of different
porosities ranging between 15-70 % undergo degradation at different rates.
Based on silicon analysis, MSVs with 60% porosity degraded completely within
30 hours, whereas MSVs with 20% porosity retained their overall structure over
40 hours (Fig. x). Therefore, low porosified particles can serve as an ideal
delivery carrier for sustained release applications. SEM images showed that
60% porosified MSVs degraded over time and the outer ring structure was first
lost and then the overall MSV size became smaller. Similarly, the pore size of
MSVs increased over time, suggesting that enlargement of pore size due to
degradation is one of mechanism by which a payload can be released from the
porous structure (Fig. 8).
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Figure 8. Degradation kinetics of MSVs. (A) Comparison of degradation
kinetics of MSVs of different porosities as analyzed by Inductively Coupled
Plasma-Atomie Emission Spectroscopy. (B) SEM images of MSVs incubated in
saline solution (pH-7.2) at 37 oC for different time points.
Reproduced with permission from J Biomed Mater Res A, Godin, B. et. al. 2010,
(44), copyright John Wiley and Sons 2010.
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1.2.3.4 Biocompatibility of MSV
Porous silicon is an attractive material (45, 46), which has been
investigated for possible applications in drug delivery by loading of nanoscale
payloads such as protein (47), enzymes (48), drugs (46, 49), and nanocarriers
(50). Unlike bulk silicon, porous silicon is highly biodegradable under
physiological conditions. The ability of the porous silicon nanostructures to
degrade into relatively harmless silicic acid byproducts presents fewer
challenges for long-term applications. Similar to other porous silicon particles,
MSVs are fully biodegradable under physiological conditions, with biologically
benign degradation products (44). In addition, biocompatibility studies of MSVs
have provided evidence that the intravenous administration of MSVs as a drug
carrier is totally safe (51).
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1.3. Adhesion molecules
Cellular adhesion molecules are expressed on the cell surface and helps
in cell-cell interaction and adhesion. Some of the most common adhesion
molecules include selectins (E-, P-, L- selectins), vascular cell adhesion
molecule 1 (VCAM-1), intracellular adhesion molecule 1 (ICAM-1), and integrins
(!v"5, !v"3). Selectins were originally named due to their selective expression
and the presence of a lectin domain in the molecule. All selectin proteins consist
of a lectin domain at the amino-terminus, followed by an EGF-like domain,
variable number of consensus repeat (CR) domains, a transmembrane portion
and ending with a short cytoplasmic tail (52). There is high homology (65%)
between the primary sequences of different selectins throughout the lectin and
EGF-like domains but the CR domains are less conserved. Their site of
expression best classifies the selectins: for example activated endothelium (Eselectin), lymphocytes (L-selectin) and platelets (P-selectin).

1.3.1 E-selectin (CD62E, ELAM-1)
E-selectin is a member of the selectin family and is specifically
synthesized by endothelial cells. In the very first experiments in 1985, treatment
of endothelial cells with cytokines as well as bacterial endotoxins resulted in a
dramatic increase in adhesion of isolated blood neutrophils and E-selectin was
identified as a participant in this process. E-selectin expression is minimal on
normal endothelial cells but the expression is induced in activated endothelial
cells in response to cytokines such as tumor necrosis factor ! (TNF-!), and
interleukin (IL)-1". E-selectin gene contains binding sites for transcription factors
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such as NF-#B and AP-1. And in the presence of cytokines, E-selectin protein
expression is rapidly induced, which peaks at 4 hours followed by a decline
within 24 hours of stimulation. This decline in expression is due to the slow
internalization and lysosomal degradation of the protein (53).

1.3.1.1 E-selectin – Expression and function
The major function of E-selectin is the recruitment of leukocytes to the site
of inflammation. Leukocytes expressing a sialylated carbohydrate ligand (sLex,
sLea) for E-selectin, bind to the inflamed endothelium via E-selectin, and roll
along the endothelial surface to subsequently transmigration to the tissue (Fig.
9). Some studies have suggested that E-selectin can also participate in the
adhesion of T-lymphocytes and monocytes to activated endothelial cells (54,
55). Abundant infiltration of leukocytes and immune cells to a tissue leads to
pathological inflammatory conditions such as diabetes, atherosclerosis,
rheumatoid arthritis and cancer. In case of cancer, infiltrated leukocytes secrete
cytokines and stimulate the activation of fibroblasts, resulting in a local invasion
through

degradation

of

extracellular

matrix

(56).

E-selectin

antagonist

(Cimetidine), a suppressor of E-selectin expression, has shown improved
therapeutic outcome in colorectal cancer patients with metastasis from cancer
cells that are sLex positive (57). In addition to E-selectin-mediated inflammation,
a flurry of recent evidence has suggested the involvement of E-selectin in
attachment and transmigration of cancer cells through the endothelium (58-60).
Disseminated cancer cells express E-selectin ligands on the surface and exploit
the E-selectin dependent recruitment mechanism to extravasate to distant site, a
process termed as vasculogenic mimicry (61). The interaction of metastatic
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cancer cells to endothelial cells via E-selectin has been shown to induce a bidirectional signaling that results in the activation of the ERK-Src pathway in the
cancer

cells

and

increased

endothelial

permeability,

facilitating

the

transendothelial migration of cancer cells (62).
Studies have shown that E-selectin is constitutively expressed on
postcapillary venules in the bone marrow endothelial cells (63) and mediates
tethering and rolling interactions through E-selectin ligands on hematopoietic
progenitor cells for their entry into bone marrow (64, 65) (Fig. 10A). This fact was
further corroborated by a study that showed that stem cells not expressing Eselectin ligands such as mesenchymal stem cells homed to the bone marrow by
engineering of their CD44 surface molecules into an E-selectin ligand (66).
Furthermore, using in vivo imaging it was recently demonstrated that E-selectin
expression in the bone marrow is discrete and discontinuous in specialized
microdomains that co-localizes with homing sites of leukemic cells (67) (Fig.
10B). E-selectin also plays a role in homing of leukemic stem cells to bone
marrow by binding carbohydrate ligands on their surface (68).
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Figure 9. Function of E-selectin in recruitment of circulating cells. Presence
of cytokines secreted from the inflammatory tissue leads to overexpression of Eselectin on the endothelial cells. Circulating cells including leukocytes and
cancer cells express E-selectin ligands (sLex, sLea), which aid in the E-selectin
mediated rolling followed by tight adhesion with other adhesion molecules such
as ICAM. This subsequently leads to arrest and transmigration of these cells into
the tissue.
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Figure 10. E-selectin expression on bone marrow endothelium. (A)
Constitutive expression of E-selectin on the bone marrow endothelium. (B) In
vivo confocal imaging shows that E-selectin expression co-localized with homing
of leukemic cells in bone marrow. Green - E-selectin, Red – Nalm-6 cells derived
from Acute Lymphoblastic Leukemia. Scale bar, 100 !m.
Reproduced with permission from Nature, Sipkins D.A et. al. 2005 (67).
Copyright Nature Publishing Group 2005.
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1.3.1.1 E-selectin ligands for targeting
The two key characteristics of E-selectin expression namely the unique
temporal and spatial expression profile and tissue specificity have prompted
substantial interest in the potential therapeutic exploitation of this protein. In an
attempt to develop tools for targeting E-selectin, numerous efforts have been
made to develop a high affinity ligand including, a monoclonal antibody (69),
peptide (70), and carbohydrate ligand (71). These ligands have shown binding to
the inflamed vasculature in both experimental animal models and clinical trials
(72). Some of these ligands have been conjugated to different types of
nanoparticles including iron oxide nanoparticles, liposomes, and micelles for
improved targeting performance to the inflamed vasculature of different disease
models including inflammatory conditions and cancer (73-75). However the use
of these ligands for active targeting remains a challenge due to various reasons,
such as low affinity and specificity, lack of serum stability, immunogenicity, and
high cost (70, 71). Therefore, E-selectin ligands that can overcome these
limitations for clinical applications for targeted delivery are highly desirable.

1.3.2 Thioated Aptamer ligands
Aptamers are structurally distinct RNA and DNA oligonucleotides that can
mimic protein-binding molecules based on their unique tertiary structures.
Aptamers against a target molecule are identified through a selection-based
process known as systematic evolution of ligands by exponential enrichment
(SELEX) first described by Gold and colleagues in 1990 (76). This process
comprises of first a synthesis of a combinatorial nucleic acid library (DNA or
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RNA), which is incubated with the desired target molecule under suitable binding
conditions. The bound aptamers are partitioned and enriched through PCR
amplification for another round of selection. Repeated iterative cycles (normally
around 10 cycles) lead to a high affinity aptamer molecule against the target
molecule of interest. Based on these characteristics such as high affinity, easy
and cost effective synthesis, long shelf-life, and minimal immunogenicity, have
made aptamers attractive alternatives to small molecule drugs and antibodies for
diagnostic and therapeutic applications (77). !
Macugen (Pegaptanib) a RNA-based molecule was the first aptamer
approved by FDA to treat age-related macular degeneration (78). However,
medical applications of unmodified aptamers are limited to transient treatment
(79) or local administration (80), due to lack of in vivo stability against nucleases
(81, 82). Therefore, for improvement of serum stability of aptamers various
chemical

modifications

incorporated

into

the

sugars

or

internucleotide

phosphodiester linkages have been successfully achieved (83-85). For example,
AS1411 a modified aptamer that binds nucleolin has shown increased in vivo
stability due to the formation of dimers and a quartet structure (86). Phase II
clinical trials of AS1411 for the treatment of real cell carcinoma are currently
underway. Similarly, aptamer conjugated nanoparticles have been successfully
used for a targeted delivery of chemotherapeutic drugs both in vitro (87) and in
vivo (88).
One of the modifications leading to nuclease-stabilized aptamers is the
sulfur substitution of phosphate oxygen on the DNA backbone, which results in
thioated aptamers or thioaptamers with higher affinity to target protein (89). This
increased affinity can be attributed to sulfur being a softer anion resulting in
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decreased interactions with solvated cations (90). Thio-substitution of the
nucleotide backbone has also shown to improve the stability of the aptamer with
no increase in toxicity (91). Thio-substitution can lead to monothioate or dithioate
aptamers (Fig. 11). Recent advances in combinatorial chemistry have enabled
the construction and screening of large random thioaptamer libraries for affinity
to proteins or other targets such as NF-IL6, HIV RT, Venezuelan Equine
Encephalitis nucleocapsid, TGF-" HepC IRES nucleic acid, NF-#B and CD44
(92-94). Based on these properties thioaptamers are attractive ligands for in vivo
targeting. The presence of positively charged amino acids on the E-selectin
protein (Fig. 12) presents an opportunity to screen thioaptamer ligands against
E-selectin, which would be very advantageous for targeting E-selectin in vivo.
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Figure 11. Structure of thioaptamers. The phosphate backbone substitution of
one of two non-bridging oxygens result in either the monothioate or dithioate
aptamers respectively.

!
Figure 12. Electrostatic surface of E-selectin protein. Blue area represents
positively charged amino acids consisting of hydrophilic-charged amino acids. Rarginine; K-lysine; E-glutamate; D-aspartate; H-histidine.
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1.4 Objectives and Hypothesis
Bone marrow is a target organ site involved in multiple diseases
including myeloproliferative disorders and malignancies such as myeloma and
metastases from primary sites such as breast and prostate. Most of these
diseases are associated with poor quality of life and the treatment options are
limited, and therefore, there is a critical need to develop effective therapeutic
strategies that allows for selective delivery of therapeutic payload to the sites of
bone marrow involvement. E-selectin is constitutively overexpressed on the
bone marrow vasculature, but almost absent in normal vessels, and therefore, Eselectin targeted drug delivery presents an ideal strategy for the delivery of
therapeutic nanoparticles to the bone marrow. Nanotechnology-based drug
delivery systems provide the opportunity to deliver drugs to the target tissue
while decreasing exposure to normal tissues.

The objective of this study was to develop a drug delivery carrier
employing nanotechnology specifically targeted to the bone marrow for the
delivery of therapeutic and imaging agents. We hypothesize that a multistage
approach based on first stage biodegradable silicon porous particles
conjugated with a high affinity E-selectin thioaptamer ligand will target
preferentially to the bone marrow.

To achieve the aforementioned goals, the following three Specific Aims are
proposed.
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Specific Aim 1: Characterization of the porous silicon multi-stage vector.
The multistage vector (MSV) was characterized in terms of size, surface charge
and biocompatibility. The biodistribution and in vivo degradation of the MSV was
analyzed. And lastly, sustained gene silencing in tumors by siRNA delivery
through MSV was demonstrated.

Specific Aim 2: Identification of high affinity E-selectin thioaptamer ligand.
A high affinity thioaptamer ligand against E-selectin was identified using a twostep screening strategy.

ESTA-1 was characterized in terms of E-selectin

binding in vitro and in vivo.

Specific Aim 3: Development of bone marrow targeted multistage vector.
ESTA-1 conjugated MSVs were developed and characterized. ESTA-MSVs
showed binding to E-selectin on cells as well as homing to the bone marrow and
subsequent delivery of therapeutic nanoparticle payload to the bone marrow
tissue.
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Chapter 2. Materials and Methods
2.1 Cell culture
The human microvascular endothelial cells (HMVECs) were a kind gift
from Dr. Rong Shao (Biomedical Research Institute, Baystate Medical
Center/University of Massachusetts at Amherst, Springfield, MA). HMVEC were
grown in endothelial basal medium-2 (Lonza, supplemented with 10% (v/v) Tetapproved fetal bovine serum, 100 U/ml penicillin and 10 mg/ml streptomycin, 1
mg/ml epidermal growth factor and 50 mg/ml hydrocortisone. Hybridoma cells
were purchased from American Type Culture Collection (Manassas, VA, cat #
HB-11684) and grown in complete growth media comprising of RPMI 1640
medium (HyClone, Waltham, MA), 90% and horse serum, 10%. Breast cancer
4T1 cells were purchased from ATCC (cat # CRL-2539) and grown in RPMI1640; (HyClone, Waltham, MA) supplemented with 10% FBS, penicillin–
streptomycin and L- glutamine. HL-60 was purchased from ATCC and grown in
Iscove's Modified Dulbecco's Medium supplemented with 20% FBS.

2.2 Development of ES-Endo cells
E-selectin cDNA was obtained (Origene, Rockville, MD) and the ORF was
amplified by PCR using the primers listed in Table 1 and ligated into TOPO Blunt
(Invitrogen, Carlsbad, CA). E-sel TOPO pBlunt was digested with Mlu I and Sal I
to E-selectin gene was inserted into pTRE-Dsred expression vector (Invitrogen,
Carlsbad, CA). A clone containing E-selectin-dsred was selected and verified to
contain the construct by double digestion with above enzymes. HMVEC were
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stably transfected with rtTA plasmid (Clontech, Mountain View, CA) and the
clones were screened with 0.5 mg of G418 for two weeks. A positive clone was
selected The selected clone was co-transfected with 15 !g of pTRE-Tight-BIhuman

E-selectin-RFP

and

puromycin

resistant

plasmid

using

using

Lipofectamine 2000 (Invitrogen, Carlsbad, CA). The cells were further incubated
in the presence of puromycin (300 ng) and the positive clone was selected by
single colony isolation and analyzed for E-selectin inducible expression.
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Table 1. List of primers used for PCR and sequencing reactions.

PCR Primers
Sense primer

GGTACCACGCGTACAATGATTGCTTCACAGTTTCTC

Antisense primer

GTCGACATCGATGGCTTAAAGGATGTAAGAAGGCTT

Sequencing primers
Position 450

CACGGTGAATGTGTAGAG

Position 901

AAAGCTGTGACATGCAGG

Position 1353

ACCTACAAGTCCTCTTGTGCC

'-!
!

2.3 Screening of E-selectin thioaptamer (ESTA-1)
2.3.1 Synthesis of thioaptamer library
ESTA was chemically synthesized as described previously (37, 95).
Briefly, sphosphoramidite chemistry in 1 µmol scale was used on a DNA
synthesizer (Experdite 8909, Applied Biosystems). The sequence of ESTA was
programmed on the synthesizer with a 3’ thioate linkage at every adenine
residue. At the end of the synthesis, 5’ end of the oligo was coupled with Cy3
phosphoramidite (Glen Research, VA) with the MMT protective group remaining.
Then the 5’-carboxy modifier-C10 (Glen Research, VA) was coupled to the 5’
end of the oligo. The oligo was cleaved from the beads and the protecting
groups were removed with 0.4M methanolic NaOH at room temperature for 2436 hr. The deprotected oligo was diluted with water and desalted in a 10,000
MWCO spin column (Amicon) at 4000 x g and dried on the lyophilizer. The oligo
was then purified on FPLC with a monoQ ion exchange column. Biotininylated
double stranded PCR products were mixed with Streptavidin coated magnetic
particles in binding bufferA (10 mM Tris-HCl, 2 M NaCl, 1 mM EDTA, at pH 7.5)
and incubated at room temperature with gentle rotation for 30 minutes according
to the manufactures instructions. The beads were washed with the binding buffer
A and followed by alkaline melting (0.1M NaOH) to separate the unbiotinylated
single stranded DNA (ssDNA) from the bead-bound double stranded DNA
(dsDNA). After purifying using spin columns the single stranded TA library was
taken in buffer B (Phosphate buffer Saline supplemented with Ca2+ and Mg2+,
and 5 mM MgCl2), denatured at 95°C and cooled on ice prior to use to favor the
formation of hairpin loop structures.
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2.3.2 Combinatorial selection of thioaptamers
The selection of TA against E-selectin was carried out by the solution
based nitrocellulose filter method as described previously (ref). Briefly, the
recombinant human E-selectin protein (240 pmoles in PBS, was mixed with a
previously nitrocellulose filtered (to exclude the sequences that bind to the
nitrocellulose) ssDNA TA library (200 pmoles) in binding buffer A was and
incubated at room temperature for 2 hours. The reaction mixture was filtered
through the nitrocellulose filter and washed 3 times with the binding buffer to
remove any unbound and weakly bound TAs. The TA-E-selectin complex
retained on the filter was eluted with 8 M urea solution. The eluent was PCR
amplified by the above-described method and analyzed by nondenaturing 15%
polyacrylamide gel electrophoresis (integrity). Stringency of the selection was
increased at each iterative cycle by decreasing the amount of E-selectin,
gradually lowering the incubation time (120 minutes at cycle 1 and gradually
reduced to 40 minutes at cycle10) and increasing the number washes. The TA
libraries obtained from rounds 5 and 10 were PCR amplified and cloned into
E.coli. Plasmids were purified and DNA sequences were isolated and a subset
of sequences was determined. The individual TA sequences were synthesized
with cyanine-3 label at the 5’ end, from the plasmids, with 5’-biotinylated forward
primer and 5’cyanine-3 labeled reverse primer by PCR amplification and used in
the binding experiments.
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2.3.3 TA binding to Endothelial cells
All binding experiments with TA were done with ES-Endo cells plated onto
plastic plate and cultured overnight to allow them to attach. After E-selectin
induction, cells were incubated with thioaptamer at indicated concentrations (10100 nM) for 15 minutes at 37 °C. The cells were washed with ice cold PBS to
remove unbound TA and fixed with 4 % paraformaldehyde for 10 minutes. The
cells were stained with 1.0 !g/mL Hoechst for 10 minutes to counterstain the
nuclei. TA binding to the cells was assessed by fluorescence microscopic
analysis (TE2000-E, Nikon, final magnification 60x). All images were acquired
under the same exposure conditions for the comparison of binding.

2.4 Purification of E-selectin antibody
Hybridoma cells were grown in complete growth media containing 10 %
FBS. Supernatant (100 ml) was collected after spinning down cells at 1200 rpm
and filtered through 0.2 !m filter followed by a centrifugation through a centricon
filter (MWCO = 30K) at 4500 rpm for 30 minutes. The fraction in the filter was
collected and pooled together. 10X PBS (1/10th volume of the collected solution)
was added to have PBS like condition for binding. 80 !l of goat anti-mouse IgG
magnetic beads (New England BioLabs, Ipswich, MA) were pre-washed with
cold PBS twice using a magnet. The supernatant from the cells was incubated
into 4 tubes containing (1/4 beads each) for overnight at 4 °C on a rotating block.
Using the magnet excess solution was removed and the beads were washed 4
times with cold PBS (100 !l each). To remove IgG bound to the beads 100 !l of
elution buffer was used and immediately after 100 !l per ml of 1M Tris (pH 7.4)
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was added to readjust pH. The solution was dialyzed with PBS for 4 hours and
collected. Finally, the solution was mixed with 15 % glycerol and aliquoted to be
stored at -20 °C.

2.5 Cell viability studies
ES-Endo cells were seeded at 10,000 per well in 96-well tissue culture
plate and with TA at indicated concentrations for 48 hours, with pre-induction
with doxycycline (1000 µg/ml) for 5 hours. For the measurement of cell viability,
10 µl MTT (5 mg/ml) was added to each well and incubated for 4 hours. The
formazan was dissolved in 150 !l of DMSO and measured by absorbance of
each well using plate reader at 490 nm.

2.6 Development of Multistage vectors (MSVs)
2.6.1 Fabrication of MSVs
MSV were fabricated by electrochemical etching of silicon wafers in the
Microelectronics Research Center at The University of Texas at Austin as
previously described (37). The physical dimensions of MSV were verified by
high-resolution scanning electron microscope.
2.6.2 Surface modification and characterization of MSVs
The modification of MSV was a three-step reaction as described
previously (96). The suspension containing MSVs was transferred to a glass
beaker and the isopropanol (IPA) was evaporated overnight using a hotplate set
at 110 ˚C. The dried MSVs were then treated with piranha solution (1 volume
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H2O2 and 2 volumes H2SO4) with heating to 110–120 ˚C for 2 h with intermittent
sonication to disperse the MSVs. Oxidized MSVs were washed in IPA, and then
suspended in IPA containing 9 % (v/v) 3’-aminopropyltriethoxysilane (APTES)
(Sigma–Aldrich, St. Louis, MO) for 16 h at 35 °C and 1300 rpm. The APTESmodified MSVs were washed in IPA and the surface charge was measured by
Zeta Pals (Brookhaven Instruments, Holtsville, NY) as described previously in
(96). The size, zeta potential and the number of MSVs was measured using a
Multisizer (Beckman) and ZetaPals instrument (Brookhaven Instruments). 2 !l of
MSVs were added to 1.4 mL of 10mM phosphate buffer (pH 7.3) and the
analysis was conducted at room temperature (23 °C) in triplicates.

2.7 Conjugation of ESTA to MSV
Conjugation of ESTA to MSV was carried out using a PolyLink Protein
Coupling Kit as per manufacturers protocol (Bangs Laboratories, Inc., Fishers,
IN). Briefly, 0.5 ml of 50 µM Cy3 labeled ESTA was incubated in 150 µL of
PolyLink Coupling Buffer. 20 µL of EDAC (200 mg/mL) and 20 µL of sulfo-NHS
(200mg/mL Pierce biotechnology) solution were added to the ESTA solution and
mixed end-over-end for 30 minutes at room temperature. 4 x 108 NH2 modified
MSV were resuspended in 0.17 mL PolyLink Coupling Buffer and added to the
ESTA solution and incubated for 4 hours at room temperature with gentle
mixing. The mixture was then centrifuged for 10 minutes at approximately 4000
x G and the pellet was resuspended and stored at 4˚C in PolyLink Wash/Storage
Buffer.
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2.8 Infrared Spectroscopy
Fourier transform infrared spectroscopy (FTIR) was preformed on a
Nicolet 6700 (Thermo Scientific, Waltham, MA) with a smart diamond crystal
attenuated total reflection (ATR) accessory. To confirm the ESTA-1 conjugation
to the MSV, the IR spectrum of ESTA-MSV was compared with ESTA and MSV
alone. Samples (105/!l) were diluted in deionized water and a 2 !L drop from
each sample was placed on the diamond crystal and subjected to vacuum. Each
sample was run for 150 scans at a resolution of 4 wavenumbers.

2.9 Flow cytometry
For analysis of E-selectin expression a 10 cm Petridish space was used
for cell culture to yield about 1 million cells. The medium was removed and cells
were washed with PBS. 5mM EDTA was added to the cells and incubated in 37
°C for 10 minutes until the cells became rounded. The cells were then scraped
using a cell lifter and collected in FACS tube. Cells were then spun down at 1500
rpm for 5 minutes to remove EDTA and re-suspended and washed twice in PBS
containing 2 % FBS. 5 !l of PE labeled anti-E-selectin monoclonal antibody (BD
# 551145) per 1 million cells was added and incubated on ice in dark for 45
minutes. Cells were then washed with PBS buffer containing FBS twice and
analyzed using the PE filter on a flow cytometer (Becton Dickinson,
FACScalibur). For fluorescent analysis of particles, 105 MSVs were incubated in
PBS and washed for two times. The fluorescence was measured on the flow
cytometer (BD Biosciences).

()!
!

2.10 Endothelial cell adhesion studies
E-selectin inducible endothelial cells (ES-Endo) were cultured as
described previously (95). For MSV adhesion studies, ES-Endo were plated on
16-well chamber slides and induced with doxycycline (2000 ng/ml) for 5 hours.
105 MSV were added to each well in the presence of complete growth media
and incubated with cells for 1 hour at 4˚C. The media was removed and the cells
were washed twice to remove unbound particles by mild shaking. The cells were
then fixed with 4 % paraformaldehyde and stained with FITC-phalloidin and
DAPI. The slide was mounted and analyzed by microscope. The number of MSV
bound per cell was counted at five different fields of view.

2.11 Loading of nanoparticles into ESTA-MSV
Quantum dots (QD 655) were purchased from Invitrogen (Cat
#Q21521MP, Carlsbad, CA) and iron oxide nanoparticles (IONs) were
purchased from Ocean Nanotech (Cat #SHA-15-05, Springdale, AR). DOPC
liposomes were developed and loaded as described previously in (96). ESTAMSVs (3–5x106) were loaded with IONs (25 !g; aminoPEG modified) in borate
buffer (25 !L), then centrifuged and washed twice in fresh borate buffer or
Millipore water. Iron oxide loading was quantified using a Prussian blue assay.
An aliquot from each sample (5 !L) was heated at 50 °C in 6N HCl (120 !L) for 2
hours with agitation to convert IONs into free iron. Iron was oxidized using
ammonium persulfate (0.1 mg/mL; BioRad, Richmond, CA) and a color reaction
was initiated by adding 5% potassium hexacyanoferrate (K4[Fe(CN)6] 3H2O)
(125 !L; Sigma–Aldrich) and incubating for 10 minutes. A standard curve was
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generated using iron (III) hexahydrate (Sigma–Aldrich, St. Louis, MO), and the
absorbance was read at 690 nm using a plate reader spectrophotometer.

2.12 Immunofluorescence
Cells were grown in chamber slides and the media was removed. The
chamber slide was disassembled and the cells were washed with PBS for 5
minutes twice at room temperature (RT). The cells were fixed with 4 %
paraformaldehyde in PBS for 15 minutes at RT. Paraformaldehye was removed
and cells were washed with PBS for 5 minutes each for three times at RT. If
required cells were permeabilized with 0.1 % Triton-X 100 in PBS for 10 minutes
and washed with PBS for 5 minutes each for three times at RT. For blocking
cells were incubated with 10 % goat serum in PBS for 1 hour at RT. Blocking
solution was removed and the cells were incubated with primary antibody (anti
E-selectin) at dilution 1:100 in 5 % goat serum in PBS for overnight at 4 °C. Cells
were washed with PBS for 5 minutes each for three times at RT and incubated
with secondary antibody (Anti-mouse 488) at dilution 1:400 in 5 % goat serum in
PBS for 30 minutes at RT. Cells were covered with aluminum foil during
incubation for all further steps. The cells were washed with PBS for 5 minutes
each for three times at RT and the nucleus was stained using Hoechst Stain
(1:2000 dilution) (Invitrogen, Carlsbad, CA) in PBS for 10 minutes RT. Cells
were washed with PBS for 5 minutes once and rinsed with water and the slide
was air dried under the foil. The slide was mounted using mounting media and
examined under the fluorescent microscope and stored in the dark at 4 °C.
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2.13 Animal studies
All animals were handled in strict accordance with good animal practice
as defined by University of Texas Health Science Center Institutional Animal
Care and Use Committee (IACUC), and all animal work was approved by the
committee.

2.13.1 Animal tumor models
Orthotopic mouse models of ovarian carcinoma were developed by
intraperitoneal injection of 106 SKOV-3ip into nu/nu animals as previously
described (97). Breast tumors were inoculated by injecting 105 4T1 cells into the
mammary fat pad of nu/nu mice.

2.13.2 Targeting studies
For in vivo targeting experiments a total of 5 x 107 MSV were
intravenously injected to mouse through the tail vein. Major organs including
liver, kidney, spleen, lung, and heart and bone marrow were harvested after 5
hours and processed for silicon contents and histological analysis.

2.14 Silicon content analysis
All the major organs were collected and lysed using RIPA buffer
containing DNAse. Organs were homogenized using a homogenizer and spun
down at 10,000 rpm for 20 minutes and washed the pellet once with water. 3 ml
of TMAH (Tetramethyl ammonium hydroxide 25 % in water, Fischer Scientific)
(,!
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was added and the samples were incubated at 50 °C for 16 hours to dissolve the
silicon particles. 500 !l of sample was dissolved in 2.5 ml DI water to measure
the silicon content using inductively coupled plasma atomic emission
spectroscopy (ICP-AES). To measure amount of silicon in injections, 10 !l of
injected particles were dissolved in 90 !l of TMAH at 50 °C for overnight and 100
!l from this solution was analyzed on the ICP. To analyze silicon in the bone
marrow, the marrow from the tibia and the femur bone was collected using an
insulin syringe with PBS. The marrow was spun down at 8000 rpm for 5 minutes
to collect cells and particles. The pellet was dissolved in 100 !l RIPA and
incubated at 55 ˚C for 24-36 hours in a shaker. The entire sample was analyzed
on the ICP. Silicon was detected at four different wavelengths of 250.69, 251.43,
251.61, and 288.158 nm and Scandium (1 ppm) was used as an internal control
for normalization. All results were expressed as percent of injected dose or
percent Si per gram of tissue.

2.15 Statistical analysis
Numerical data were expressed as means ± standard error. Statistical
differences between the means for the different groups were evaluated with
Microsoft Office Excel using either the Student’s T-test or analysis of variance
(ANOVA), with the level of significance at p < 0.05.
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Chapter 3. Experimental Results
3.1. Properties of MSV
3.1.1 Physico-chemical properties of MSV
Our group has successfully fabricated porous silicon multistage particles
(MSV) with different size and shapes using a combination of standard
electrochemical etching and photolithographic techniques as summarized in the
schematic (Fig. 13). Since the focus of this study is vasculature targeting of
MSV, quasi-hemispherical shaped MSVs were fabricated based on the rational
design to enhance interaction with the vasculature as described in detail in the
introduction.
MSVs used in this study were first characterized by different techniques.
Scanning electron micrograph (SEM) images showed that the average diameter
of quasi-hemispherical MSV was 1.6 ± 0.1 !m with pore size of 30 nm (Fig. 14AD). Reproducibility of the geometry of MSV was verified by size distribution
analysis using a multisizer (Fig. 15) and all the counting and sizing of MSVs for
subsequent experiments was carried out using the multisizer.
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Figure 13. Schematic outline of the fabrication protocol for MSV.
Combination of photolithography based microfabrication and electrochemical
etching. (A) A silicon substrate masked with silicon nitride is patterned through
photolithography; (B) pattern is transferred and trenches are formed in the
silicon by reactive ion etch; (C) the electrochemical etching results in selective
porosifiication, and (D) the particles are released from the substrate by
sonication.
Reproduced by permission from Biochimica et biophysica acta, Serda, et al,
2010 (98). Copyright Elsevier 2010.
!
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Figure 14. SEM images of porous MSVs with different magnifications. (A)
Image of a collection of MSVs; (B) Single MSV; (C) Cross-section of a MSV; (D)
Close-up view of the porous structure of a MSV.
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Figure 15. Size distribution of MSVs. MSVs were re-suspended in IPA and the
size was measured on a multisizer with three repetitive runs to analyze (A) mean
diameter; and (B) volume equivalent of a spherical particle.
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3.1.2 Biodistribution and biodegradation of MSV
To examine the biodistribution of MSV, the mice were injected with MSV
intravenously, and the major organs including liver, kidney, spleen, lung, and
heart were harvested 5 hours after the injection. Silicon content analysis
demonstrated that MSV primarily accumulated in the liver (48 %) and spleen (17
% of total injected dose), and there was minimal MSV accumulation in the
kidney, lung, heart and the born marrow (Fig. 16). However, based on our
microscopic analysis, there was no evidence of embolization of MSV in the
capillaries.
After analyzing the bio-distribution of intravenously injected MSVs, the
next step was to examine in vivo biodegradation of MSVs in the liver and spleen.
For this the silicon content in these organs was measured at different time
points. Silicon content in the spleen reduced by 80 % in the first two weeks and
cleared by the third week (Fig. 17). In contrast, only 55 % of MSV was cleared
from the liver in the first two weeks, and approximately 25 % of the injected MSV
remained in the liver 3 weeks after injection (Fig. 18), suggesting that MSV
degradation kinetics are different in each organ.

SEM images of the MSV

showed enlargement of pore size at day 7 and reduction of overall size by day
14 (Fig. 18).

Collectively, these data suggest that the MSV can serve as

reservoir to protect its payload from degradation, and release them over time by
a mechanism that combines degradation of the carrier material, and hindered
diffusion through the nanoporous structure.
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Figure 16. Biodistribution of MSV. Silicon content analysis of organs isolated
from mice (n = 6) following i.v. injection of MSV. The major organs including
heart, lung, liver, kidney, and spleen were harvested 4 h after the i.v. injection.
Silicon amount was measured by inductively coupled plasma atomic emission
spectroscopy and expressed as % of injected dose per organ (% ID). n.d., not
detected.
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Figure 17. Biodegradation of MSV. (A) Silicon contents in the liver and (B)
spleen after i.v. injection of MSV at different time points. Silicon amounts were
expressed as % of injected dose per organs (% ID).
Reproduced with permission from Cancer Research, Tanaka et al, 2010, (96).
Copyright American Association of Cancer Research 2010.
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Figure 18. In vivo degradation of MSVs. SEM image of MSVs isolated from
the liver and spleen after 7 and 15 days of injection. (Original magnification= x
50000).
Reproduced with permission from Cancer Research, Tanaka et al, 2010, (96).
Copyright American Association of Cancer Research 2010.
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3.1.3 Sustained delivery of siRNA contained in MSV
Based on the unique biodistribution and sustained biodegradation
properties in vivo, we next tested if a payload incorporated into the MSV could
be released for a sustained period of time. For a proof of principle we tested
siRNA delivery to achieve sustained gene silencing. For this we first
demonstrated siRNA encapsulated into nanoliposomes could be incorporated
into the MSV. Fluorescently labeled siRNA with Alexa 555 were encapsulated
into nanoliposomes and loaded into the silicon particles (Fig. 19). The image
demonstrated that nanoliposomes containing fluorescently labeled siRNA were
effectively incorporated into the porous particles and intensive fluorescence was
observed in the majority of the particles as seen in Figure 19.

Figure 19. Liposome loading into MSVs. Fluorescent (A) and phase (B) view
of siRNA encapsulating liposomes incorporated into MSVs
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To highlight the feasibility of the multistage delivery system, nanoliposomes were
effectively incorporated into the MSVs (with 1.6 !m diameter, 60 % porosity, and
40 nm pore size) and for proof of concept the delivery of a liposome
encapsulating siRNA for the sustained silencing of the gene was tested. The
gene selected for this study was EphA2 an oncogenic tyrosine kinase receptor
overexpressed in ovarian cancer (97).
To test this delivery, mice bearing orthotopic tumors derived from
SKOV-3 cells (15 days after intraperitoneal inoculation of tumor cells) were
injected with 3 x 107 MSVs loaded with nanoliposome/EphA2-siRNA (15 !g of
siRNA: triple dose). As a comparison, EphA2 siRNA encapsulated liposomes (5
!g of siRNA) were injected twice weekly as per a previously published study
(97). Tumors were harvested at 3, 7, 14, and 21 days and EphA2 expression
was analyzed by immunohistochemistry (Fig. 20). EphA2 expression was
downregulated until 21 days (96). Moreover, the biological effect of sustained
downregulation of EphA2 was determined by assessing the microvessel density
(CD31) and cell proliferation (Ki67) (Fig. 21). Both microvessel density (a and c)
and cell proliferation (b and d) were significantly reduced in tumor when treated
with a single administration of the MSV-loaded with EphA2 siRNA encapsulated
liposomes **P<0.001 (Fig. 21). Similar effect by EphA2 siRNA encapsulated
liposomes alone was achieved by three times the siRNA dosage (twice a week
injections).
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Figure 20. Systemic delivery of EphA2-siRNA using MSV. Mice (n=3 per time
point) bearing SKOV3ip1 orthotopic ovarian tumors were injected with MSVEphA2-siRNA or left nontreated. Immunohistochemical analysis of EphA2
expression in the SKOV-3 tumor. Images were taken at original magnification of
"400.
Reproduced with permission from Cancer Research, Tanaka et al, 2010, (96).
Copyright American Association of Cancer Research 2010.
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Figure 21. Effect of sustained siRNA delivery on angiogenesis and cell
proliferation. Tumors from animals with the SKOV3ip1 ovarian tumor were
examined for (A) microvessel density (CD31) and (B) cell proliferation (Ki67).
Representative sections from each treatment group are shown (final
magnification= x100 for CD31 and x400 for Ki67), with mean number of vessels
per field or mean % of proliferative cells, summarized in the graph at the bottom
(C-D). Five different fields per slides at least three individual tumors per
treatment group were examined.
Cont si – control siRNA, EphA2 si – siRNA against EphA2, L - liposome.
Reproduced with permission from Cancer Research, Tanaka et al, 2010, (96).
Copyright American Association of Cancer Research 2010.
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3.1.4 Biocompatibility of MSV loaded EphA2-siRNA
We next tested the biocompatibility of multistage delivery system following
i.v. administration of therapeutic dose of MSV-EphA2-siRNA. The cytokine levels
in the plasma were analyzed after 5 hours post injection. Cytokine levels in the
mice injected with MSV-EphA2-siRNA were similar to other controls (Fig. 22).
Interestingly, liposome injection alone (both L-control siRNA and L-EphA2
siRNA) resulted in elevation in GM-CSF levels, which did not occur for MSVEphA2-siRNA injection. These data indicate that MSV-loaded liposomal siRNA
induced no significant levels of inflammatory cytokines and on the contrary
reduced liposome-mediated inflammatory response.
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Figure 22. Cytokine analysis of MSV loaded liposome-siRNA. Following i.v.
injection of MSV-EphA2-siRNA into FBV/N mice (n=4), the serum was collected
5 hours after injection and the plasma was analyzed for different inflammatory
cytokines. Data represented as picograms/ml of plasma.
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3.2. Identification of E-selectin thioaptamer
3.2.1 Synthesis of thioaptamer library
A single-stranded library consisting of ~1014 different sequences was
chemically synthesized from a 73-mer DNA template containing a 30-nucleotide
random region flanked by 21-mer and 23-mer polymerase chain reaction (PCR)
primer regions.

5’ Primer –

N30 –

Primer 3’

(1014 sequences)

The library was PCR amplified using a mixture of dATP, dTTP, dCTP, and
dGTP and biotinylated forward primer to obtain a thio-substituted library. The
resulting PCR products contained monothio-phosphate substitutions (in the Sp
configuration) on the 5’ side of every dA residue with the exception of the primer
region on the non-template strand. These double stranded PCR products were
then incubated with streptavidin-coated beads to separate the unbiotinylated
single strand from the double stranded DNA. The combinatorial library was next
used to screen for a thioaptamer ligands against E-selectin.
For the identification of E-selectin thioaptamer, a two-step selection
strategy comprising of a recombinant protein-based screening followed by a cellbased selection was employed.
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3.2.2 Screening with recombinant E-selectin protein
The TA that binds to E-selectin recombinant protein was screened from
the TA library using a solution-based filter binding method. The recombinant
human E-selectin protein was incubated with TA library and filtered through the
nitrocellulose membrane to remove unbound TAs. The TA-E-selectin complex
retained on the filter membrane was eluted and used as the template for PCR
amplification. This selection cycle was repeated for a total of 10 times and the
stringency of the selection was elevated gradually at each iterative cycle by
decreasing the amount of E-selectin protein and incubation time (Fig. 24). The
TA libraries obtained after round 5 and 10 were PCR amplified and subcloned
into plasmid vector for DNA sequences. After 10 iterative cycles a total of 35 TAs
were isolated and sequenced. Based on their primary sequences, the TAs were
aligned using ClustalW algorithm (Fig. 24) and a cladogram tree was generated
in which the 35 sequences were grouped into 14 families (Fig. 25). Based on the
lowest predicted free energy of the secondary structures of the TAs, one TA
from each family was selected and common sequence motifs were identified
(Fig. 26). These 14 TAs were amplified by PCR with Cy-3 labeled reverse primer
for the second step of cell-based selection to identify the TA sequences that
specifically bind to E-selectin on the surface of endothelial cells.
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Figure 23. Schematic representation of the iterative process to screen
thioaptamers. The process is based on the SELEX process where the TA
library is incubated with the target protein. The bound DNA is enriched after
repeated washing steps and amplified by PCR reaction. The cycle is iteratively
repeated several times to isolate high binders to target protein.
!
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Figure 24. ClustalW alignment of the selected sequences after 10th round.
After the 10th round of selection, 35 clones were selected and their sequences
were identified. The PCR primer regions in the sequences are underlined.
Reproduced with permission from PLoS ONE, Mann et al, 2010, (96). Copyright
Public Library of Science 2010.
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Figure 25. Cladogram of the selected sequences after round 10. The
sequences from 10th round of selection was aligned by ClustalW. Based on the
Phylogeny of the sequences they were grouped into 14 different families.
Reproduced with permission from PLoS ONE, Mann et al, 2010, (96). Copyright
Public Library of Science 2010.
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Figure 26. Common sequence motifs among 14 TA candidates. (A) The 14
sequences belonging to each family from the cladogram are aligned by ClustalW
program. (B) Common sequence motifs identified among the 14 sequences.
Reproduced with permission from PLoS ONE, Mann et al, 2010, (96). Copyright
Public Library of Science 2010.
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3.2.3. Cell-based TA screening
The second step in the screening was a cell-based selection of the 14
TAs identified in the first step (81). To identify the TA sequences that bind to Eselectin on the surface of endothelial cells, there were two strategies that were
considered for achieving over expression of E-selectin on the surface of
endothelial cells
1. Induction of cells with cytokines like TNF-!, IL-1" (69, 99)
2. Development of an inducible system of cells to precisely control
expression of E-selectin

The limitation of induction of E-selectin by cytokines is that firstly, it results
in non-uniform stimulation of E-selectin in cells and secondly, it also causes
upregulation of multiple surface molecules which can interfere in the screening
of E-selectin specific thioaptamer ligands. For these reasons, a Tet-on inducible
E-selectin endothelial cell line (ES-Endo) was developed (Fig. 27).

3.2.3.1 Development of E-selectin inducible endothelial system
A) Construction of E-selectin expression vector
The following steps were carried out for the construction of E-selectin expression
vector:
•

The cDNA of E-selectin was obtained and the E-selectin ORF was
amplified by PCR and cloned into TOPO blunt vector.

•

Positive clones containing the gene were selected and sequenced and
verified with Pubmed database (Accession NM_000450). The gene

+%!
!

sequence of E-selectin positive clone was 100% intact and no mutation
was observed.
•

E-sel TOPO pBlunt was digested with Mlu I and Sal I to obtain the Eselectin gene for subsequent insertion into pTRE-Dsred expression vector
(Fig. 27A)

•

A clone containing E-selectin-dsred was selected and verified to contain
the construct by double digestion with above enzymes

•

The function of the pTRE-Tight-BI hE-selectin-RFP positive clone was
confirmed by transient transfection of the plasmid into tet-on MDA-MB231 breast cancer cell line established previously (100), and the cells
were treated with 1000ng of doxycycline overnight.

•

MDA-MB-231 cells expressed red fluorescence protein in response to
1000ng doxycycline (Fig. 27B). This data supports that the isolated pTRETight-BI hE-selectin-RFP positive clone was functional.
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Figure 27. Construction of E-selectin expression vector. (A) Plasmid map of
pTRE-Tight-BI human E-selectin-RFP. (B) transient transfection of pTRE-TightBI human E-selectin-RFP plasmid in Tet-on MDA-MB-231 cells. (C) Mechanism
of Tet-on inducible system.
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B) Development of Tet-on endothelial cells
Two immortalized human endothelial cell lines were tested (HMVEC and
HMEC) for developing an E-selectin inducible cell line. Human microvasculature
endothelial cell line (HMVEC) was previously immortalized by stable transfection
of telomerase reverse transcriptase (TERT) gene (101) and the human dermal
microvasculature endothelial cell line (HMEC) was immortalized by SV-40 (102).
First, immunofluorescence was performed to test the basal expression
level of E-selectin in these human endothelial cell lines. Both HMVEC and
HMEC were incubated in the presence of 10 !g of TNF-! for 5 hours to induce
E-selectin expression. After brief fixation, the cells were stained with antibody
against E-selectin. E-selectin expression was rapidly induced by proinflammatory cytokine (TNF-!) in both HMVEC and HMEC cells (Fig. 28).
However, the baseline E-selectin expression level for HMVEC cells was minimal,
and the induction of E-selectin expression was very scattered and was only seen
in a total of 20-30 % of the cells (Fig. 28). This data suggests that E-selectin
induction by cytokine through NF-#" may require additional cellular mechanisms.
In contrast, HMEC cells responded to TNF-! induction more sensitively and
evenly, however, the basal E-selectin expression level was higher than HMVEC.
HMVEC cells with much lower baseline expression of E-selectin than HMEC
were selected for development of E-selectin inducible system.
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Figure 28. Immunofluorescencne of E-selectin in two endothelial cell lines
(HMEC and HMVEC). Cells were induced with TNF (10 ng/ml) for 5 hours and
fixed and stained for E-selectin expression. Green - E-selectin and Blue Hoechst 33342.
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Next, HMVEC were stably transfected with an rtTA plasmid and the
positive clones were screened. To confirm the expression and function of the
rtTA protein, the clones were infected with 50 MOI of adenoviral TRE-#galactosidase with 1000 ng of doxycycline treatment. The #-galactosidase
activity in the clones was measured using ONPG as the substrate. Clone 32
showed the highest activity (Fig. 29A). To further confirm the expression of rtTA,
western blotting was performed using antibody against rtTA and clone 32
showed the highest rtTA expression level (Fig. 29B). As a second step of the
cloning, the clone 32 was co-transfected with pTRE-Tight-BI-human E-selectinRFP and the stable clone was isolated after two weeks. The stable clone
expressed the RFP after treatment with doxycyline as visualized by fluorescent
microscopy (Fig. 29C).

To examine the ability to induce E-selectin overexpression in the stable
HMVEC clone of Tet-on inducible bi-directional RFP/E-selectin, the cells were
incubated with 1000 ng of doxycycline for 5 hours and E-selectin expression was
determined by immunofluorescence and western blotting (Fig. 30). E-selectin
was expressed on the surface of the cells in response to doxycycline, whereas
no E-selectin expression was seen without treatment with doxycycline.
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Figure 29. Development of tet-on E-selectin inducible endothelial cells. (A)
Screening of tet-on positive cells. (B) Tet-on protein expression in HMVEC clone
32. (C) RFP expression in HMVEC clone 32 in response to doxycycline.
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Figure 30. Doxycyline inducible E-selectin expression in ES-Endo.

(A)

Immunofluorescence to analyze E-selectin expression in ES-Endo after
induction with doxycycline 1000 ng/ml Green – E-selectin; Blue - Hoechst 33342.
(B) Western blotting of E-selectin protein expression in the ES-Endo cells after 5
hour induction with doxycycline.
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3.2.3.2 TA selection using E-selectin inducible endothelial cells
To utilize the E-selectin inducible endothelial cells (ES-Endo) for the
second step of TA selection, first the doxycycline dose dependent induction of Eselectin expression was analyzed. For this induction in E-selectin expression on
the plasma membrane was analyzed on ES-Endo incubated with increasing
concentrations of doxycycline (0–2000 ng/ml) for 5 hours. As a reference for the
physiological level of E-selectin expression, the cells were also treated with TNF! (10 ng/ml) for 5 hours. E-selectin expression was analyzed using
immunofluorescent staining with anti-E-selectin antibody. When treated with 500
ng/ml of doxycycline, upregulation of E-selectin expression was observed
predominantly on the cell membrane, and the expression level increased in a
doxycycline concentration dependent manner (Fig. 31). At doxycycline
concentration of 2000 ng/ml, the level of E-selectin expression was the highest
and equivalent to TNF-! treated cells therefore this concentration of doxycycline
was used for all the subsequent experiments. Due to the leakiness of the
inducible system, the baseline level of E-selectin expression was slightly higher
than wild type cells in the absence of doxycycline.
Next step was to select out of the 14 TAs isolated in the first step, the TA
that binds to E-selectin specifically. For this ES-Endo were pre-incubated with
doxycycline and then with each of the 14 TAs (100 nM) were added for 20
minutes at 37 °C. To analyze the binding and specificity of each TA, the
fluorescent intensity associated with the cells was compared using fluorescent
microscopy (Table 2).
Between the 14 TAs tested, TA-1 exhibited the highest binding, and this
binding was doxycycline dose-dependent. The number and brightness of the
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speckles increased proportionally to the doxycycline concentration up to 2000
ng/ml (Fig. 31), suggesting E-selectin specific binding. Similar binding pattern of
TA-1 was also observed with TNF-! induction of ES-Endo. Although all the TAs
were isolated based on their ability to bind human recombinant E-selectin
protein, the rest of the TAs showed weak doxycycline dependent with high
background binding (TA 20, 31) (Table 2). Based on these results, TA-1 was
selected as the top candidate for E-selectin thioaptamer 1 (ESTA-1) and further
characterization studies of ESTA-1 were conducted.
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Table 2. Comparison of TA binding to E-selectin expressing ES-Endo. The
table shows the calculated lowest free energy using MFold algorithm for each 14
TA sequences, their relative binding, and relative specificities to E-selectin
expressing cells. The relative binding affinity was determined by the amount of
fluorescence detected per field of view (final magnification 60x) in the cell based
binding assay and the relative specificity was defined by the degree of
doxycycline dose dependent effect on TA binding. + indicates the binding
strength or specificity.
Reproduced with permission from PLoS ONE, Mann et al, 2010, (96). Copyright
Public Library of Science 2010.
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Figure 31. E-selectin dependent binding of ESTA-1. ES-Endo cells were
induced with different concentrations of doxycycline (0-2000 ng/ml) and
analyzed

for

E-selectin

expression

and

ESTA-1

binding.

E-

selectin

overexpressing ES-Endo cells were incubated with Cy3-labeled ESTA-1 (100
nM) for 20 minutes at 37 °C. TNF-! (10 ng/ml) induced ES-Endo was used as a
positive control. Blue, Hoechst 33342; Red, Cy3-labeled ESTA-1; Green, Eselectin.
Reproduced with permission from PLoS ONE, Mann et al, 2010, (96). Copyright
Public Library of Science 2010.
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We did two experiments to confirm that ESTA-1 binding on the ES-Endo
cells was E-selectin specific. Firstly, we treated ES-Endo with different
concentrations of E-selectin monoclonal antibody followed by incubation with
100 nM of ESTA-1. Pre-treatment and co-incubation with E-selectin antibody
caused a significant reduction of ESTA-1 binding to ES-Endo as confirmed by
the disappearance of the speckle pattern (Fig. 32). In contrast, there was no
affect of normal IgG pre- treatment on ESTA-1 binding to the cells (Fig. 32). This
data confirms that E-selectin antibody shares the binding site with ESTA-1 on
the E-selectin protein.
Secondly, immunofluorescence of E-selectin was performed on induced
ES-Endo that were incubated with ESTA-1. For this a different monoclonal
antibody against E-selectin was used that does not compete with ESTA-1
binding. Partial colocalization of ESTA-1 (red fluorescence) with E-selectin
(green fluorescence) was observed on the edge of the cells as seen in yellow
merge, supporting ESTA-1 binding to E- selectin on the cell surface (Fig. 33).
One of the possible reasons for only a partial colocalization of ESTA-1 and Eselectin can be the intracellular uptake of ESTA-1 following the initial cell surface
binding. In fact, it is well documented that E-selectin undergoes recycle phase
and is internalized to the intracellular organelles (endosomes and lysosomes)
[34]. Confocal microscopy suggested that ESTA-1 maybe internalized as
evidenced by appearance of speckles at different heights (Fig. 33B). These data
confirmed that ESTA-1 binds to E-selectin protein.
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Figure 32. Competitive E-selectin binding of ESTA-1 and E-selectin
antibody. Blocking of ESTA-1 binding by E-selectin antibody. ES-Endo were
pre-incubated (top panel) or co-incubated (bottom panel) with 25 mg of Eselectin antibody for 2 hours and incubated with 100 nM of ESTA-1 for 20
minutes. Unbound ESTAs were washed away and slides were prepared for
fluorescent imaging to visualize the binding to ES-Endo cells. Blue, Hoechst
33342; Red, Cy3-labeled ESTA-1; Green, E-selectin.
Reproduced with permission from PLoS ONE, Mann et al, 2010, (96). Copyright
Public Library of Science 2010.
!
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Figure 33. Colocalization of E-selectin expression and ESTA-1 binding. (A)
ES-Endo cells were treated with doxycycline (2000 ng/ml) and analyzed for
ESTA-1 binding and E-selectin expression using immunofluoroscence. Blue,
Hoechst 33342; Red, Cy3-labeled ESTA-1; Green, E-selectin. (B) Confocal
image of ESTA-1 binding to doxycycline induced ES-Endo cells. Red, Cy3labeled ESTA-1; Green, Cytox nuclear staining.
Reproduced with permission from PLoS ONE, Mann et al, 2010, (96). Copyright
Public Library of Science 2010.
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3.2.4 Characterization of ESTA-1
Next, ESTA-1 primary sequence was analyzed (Figure 34A). Based on
our analysis this sequence did not show any homology to the existing genes in
the NCBI database. The predicted secondary structure of ESTA-1 was
determined using the MFOLD computer simulation program (103). Based on
MFOLD prediction, the structure of the ESTA-1 comprised of two stable hairpin
loops with an estimated free-energy change of folding of -10.72 kcal/mol (Fig.
34B). Preliminary deletion studies of the stem loops suggest that these loops
played an important role in binding to the E-selectin protein.
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Figure 34. ESTA-1 sequence and the MFOLD predicted secondary
structure. (A) ESTA-1 DNA sequence. All of the deoxy adenosine (dA) residues
are modified monothio substituted with Rp configuration, with the exception of 5’primer binding region in the sequence. (B) MFOLD predicted secondary
structure of ESTA-1.
Reproduced with permission from PLoS ONE, Mann et al, 2010, (96). Copyright
Public Library of Science 2010.
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3.2.5 Evaluation of binding affinity of ESTA-1 to E-selectin
The binding affinity of ESTA-1 with all selectins was determined using
electrophoretic mobility shift assay (EMSA). In this experiment, fixed amounts of
ESTA-1 (4.6 pmoles) was mixed with increasing amounts (up to 22 pmoles) of
recombinant proteins (E-, P-, L-selectin) to form a DNA/protein complex. The
amount of ESTA-1/E-selectin protein complex formation was analyzed using
EMSA. This complex increased when higher amount of recombinant E-selectin
was added to the reaction with a corresponding decrease in the free (unbound)
ESTA-1. Notably the amount of this complex reached saturation when the molar
ratio of ESTA-1/E-selectin was 1:1. Based on the densitometric analysis of the
unbound ESTA-1, the KD for ESTA-1 binding to E-selectin was estimated to be
47 nM (Fig. 35A). Contrary to this, the binding of ESTA-1 to P-selectin showed
very low affinity (estimated KD= 13 !M) under the same conditions and there was
no detectable binding to L-selectin (Fig. 35B).
The nanomolar range of binding affinity of ESTA-1 for E-selectin on the
endothelial cells was further confirmed under biological conditions, by incubating
different concentrations of ESTA-1 (50 nM - 200 nM) with ES-Endo cells induced
with doxycycline. A doxycycline dose dependent increase of ESTA-1 binding to
the cells was observed that reached a maximum at 200 nM (Fig. 35C).
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Figure 35. Evaluation of binding affinity of ESTA-1 to E-selectin. ESTA-1
(4.6 pmoles) and recombinant human E-selectin protein (up to 19 pmoles) were
incubated and subjected to electrophoresis at 4 °C. The gels were stained with
SYBR Gold nucleic acid stain and densitometric analysis of the unbound ESTA1 was plotted. (A) E-selectin recombinant protein. (B) P-selectin recombinant
protein. (C) ESTA-1 concentration dependent binding to ES-Endo. ES-Endo
were incubated with doxycycline (1000 ng/ml) for 5 hours and then with indicated
concentrations of Cy3-labeled ESTA-1 for 20 minutes. ESTA-1 binding was
analyzed by fluorescent imaging. Red, Cy3-labeled ESTA-1; blue, Hoechst
33342.
Reproduced with permission from PLoS ONE, Mann et al, 2010, (96). Copyright
Public Library of Science 2010.
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3.2.6 ESTA-1 binding to vascular E-selectin in vivo
Next step was to deztermine if ESTA-1 binds E-selectin in vivo. As
mentioned earlier, E-selectin is constitutively expressed on bone marrow
endothelium and in the normal organs; E-selectin is upregulated in the presence
of inflammatory stimuli such as in the case of cancer. So prior to examining the
ESTA-1 binding to these sites we first examined the E-selectin expression at
these sites.
Firstly, bone marrow was isolated and immunohistochemical analysis was
performed on paraffin-embedded sections that confirmed high constitutive Eselectin expression (Fig. 36A). These results are consistent with earlier
published studies. Next, ESTA binding to E-selectin on the bone marrow
endothelium was examined. ESTA-1 labeled with Cy-3 dye was intravenously
injected into mice and the bone marrow was isolated and analyzed by a
fluorescent microscope. A significantly high accumulation of ESTA-1 was
observed in the bone marrow tissue (Fig. 36B). ESTA-1 accumulation in other
organs was minimal.
Similarly, a 4T1 breast tumor mouse model immunohistochemistry was
performed to determine E-selectin expression. 4T1 tumor is characteristic for the
presence of infiltrating leukocytes and macrophages. A high E-selectin
expression was observed on the endothelial cells of the tumor-associated
vasculature (Fig. 37A). Next, Cy-3 labeled ESTA-1 was intravenously injected
into 4T1 mouse model, and the tumor was analyzed for ESTA-1 binding. ESTA-1
binding to the tumor vasculature was observed as evidenced by the speckled
and punctate red pattern (Fig. 37B). No significant binding of ESTA-1 was
observed in other organs including liver, spleen, kidney, lung, and heart. To
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confirm that this was E-selectin specific binding, a pre-injection of E-selectin
monoclonal antibody significantly reduced the ESTA-1 binding. Pre-injection of
control IgG did not cause any inhibition in ESTA-1 binding.

-'!
!

Figure 36. In vivo binding of ESTA-1 to bone marrow vasculature. (A)
Immunohistochemical analysis of paraffin embedded sections to analyze Eselectin expression on the vasculature of bone marrow. (B) In vivo binding of
ESTA-1 to bone marrow vasculature. Bone marrow was isolated from the
animals (n=3) and analyzed under a fluorescent microscope. Red, Cy3-labeled
ESTA-1; blue, Hoechst 33342.
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Figure 37. In vivo binding of ESTA-1 to tumor vasculature. Sections derived
from 4T1 xenograft model were examined for E-selectin expression and ESTA-1
binding. (A) Immunohistochemical analysis of paraffin embedded sections to
analyze E-selectin expression on the vasculature of 4T1 xenograft. (B) ESTA-1
binding to 4T1 tumor vasculature. ESTA-1 was injected to mice (n = 3) via tail
vein and tumor was isolated and the frozen sections (5 mm) were prepared to
assess distribution of ESTA-1. Red, Cy3-labeled ESTA-1; blue, Hoechst 33342.
Reproduced with permission from PLoS ONE, Mann et al, 2010, (96). Copyright
Public Library of Science 2010.
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3.2.7 ESTA-1 binding to human tumor vasculature
Due to species differences in human and mouse selectin, ESTA-1 binding
to the tumor vasculature using histological sections derived from human
carcinomas

was

tested.

Immunohistochemical

analysis

confirmed

that

approximately 70-80% of skin, ovarian and breast tumors showed positive Eselectin expression on the vasculature (Fig. 38 A and C). The incubation of the
frozen sections with ESTA-1 showed intense binding on the vessels in ovarian
carcinomas as evidenced by the co-localization with CD31 (Fig. 38B). In
contrast, ESTA-1 binding was not observed in normal vessels. Similarly, high
ESTA-1 binding was also observed to the tumor-associated vasculature in skin
and breast carcinomas (Fig. 38C). ESTA-1 binding was almost absent in the
normal human tissues, including the adrenal, pancreas, brain, lung, temporal
lobe, breast, cervix, heart, kidney, stomach, thyroid, liver, placenta, salivary
gland, skeletal muscle, small intestine, spleen, and uterus.
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Figure 38. ESTA-1 binding to the human tumor vasculature. Frozen sections
derived from human ovarian carcinomas and normal ovaries were examined for
E-selectin expression and ESTA-1 binding. (A) Immunohistochemical analysis
for E-selectin expression on the vasculature of ovarian carcinoma. (B) ESTA-1
binding to tumor vasculature of ovarian carcinoma. Green, CD31; Red, Cy3labeled ESTA-1; Blue, Hoechst 33342. (C) Correlation of ESTA-1 binding to the
tumor vasculature and E-selectin expression in human carcinomas derived from
breast, ovary, and skin.
Reproduced with permission from PLoS ONE, Mann et al, 2010, (96). Copyright
Public Library of Science 2010.
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3.2.8 Effect of ESTA-1 binding on cell adhesion
Since E-selectin plays a critical role in cell adhesion, we next tested if
ESTA-1-binding to E-selectin mediated inhibition of cell adhesion to endothelial
cells. For this study, adhesion of a sLex positive human promyelocytic cell line
(HL-60) on ES-Endo was analyzed. On induction of ES-Endo with doxycycline
the HL-60 cell adhesion to cells increased by 5-fold (Fig. 39A). HL-60 adhesion
to ES-Endo pre-incubated with indicated concentration of ESTA-1 for 20 minutes
was compared with untreated cells. Preincubation of ES-Endo with ESTA-1 (100
nM) resulted in inhibition of HL-60 adhesion to induced ES-Endo by 80 % (Fig.
39A) (p<0.01). The IC50 for the inhibition of this interaction was approximately 63
nM. This data indicates that ESTA-1 interaction to E-selectin competes with
binding of natural ligands such as sLex and therefore ESTA-1 can have a
potential application as an antagonist of E-selectin mediated adhesion during
inflammation.

3.2.9 Effect of ESTA-1 on cell viability
Lastly, for in vivo applications of ESTA-1, the effect of ESTA-1 treatment
on the cell viability of ES-Endo cells was tested. Cells were first stimulated with
doxycycline and then incubated with increasing concentration of ESTA-1 (up to
200 nM) for up to 48 hours. To test cell viability during this treatment, a MTT
assay was performed. There was no reduction in cell viability at least up to 200
nM of ESTA-1 for 48 hours incubation with ESTA-1 (Fig. 39B). Also this
treatment did not cause any visible morphological changes associated with
cytotoxicity in the cells. Therefore, ESTA is a biocompatible material and can be
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tested for its in vivo applications. With this data, we next developed ESTA-1
conjugated MSV to attempt targeted delivery to the bone marrow.
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Figure 39. Effect of ESTA-1 binding on cell adhesion and cell viability. (A)
ES-Endo were incubated with doxycycline (1000 ng/ml) for 5 hours followed by
different concentrations of ESTA-1 (1 - 200 nM) for 30 minutes. HL-60 cells were
incubated with ES-Endo and the adhesion of HL-60 cells was quantified. Error
bars, mean ± SEM; *,P<0.05, **, P<0.01 vs. Dox+/ESTA-, Student’s t test. (B)
ES-Endo were incubated with doxycycline (1000 ng/ml) for 5 hours followed by
different concentrations of ESTA-1 (1 - 200 nM) for 30 minutes. The cells were
washed and incubated with MTT for 4 hours, and the absorbance at 570 nm was
measured. The data was normalized by untreated cells (without ESTA-1) as
100%. . Error bars, mean ± SEM.
Reproduced with permission from PLoS ONE, Mann et al, 2010, (96). Copyright
Public Library of Science 2010.
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3.3 Development of bone marrow targeted MSV
3.3.1 Conjugation and characterization of ESTA-MSV
The MSVs fabricated as part of Aim 1 were functionalized by 3’aminopropyltriethoxysilane (APTES) to introduce amine groups on the surface to
serve as a linker for conjugation with E-selectin thioaptamer molecule (ESTA).
ESTA containing a 5’ carboxyl group was conjugated to the amino functionalized
MSV as schematically represented in Fig. 40A. Initial confirmation of conjugation
was done by visualizing the fluorescent ESTA-MSVs under a fluorescent
microscope (Fig. 40B).
To validate the conjugation of ESTA to MSV, physico-chemical properties
of ESTA-MSV were measured using three independent methods. Analysis of
zeta potential showed that the surface charge of MSV changed from +6mV of
amine modified MSV to -35 mV of ESTA-MSV. This change in the surface
charge was attributed from the presence of DNA on the surface of MSV. To
confirm the conjugation of ESTA to the MSV, the fluorescence of the Cy3-labled
ESTA conjugated MSV was examined using flow cytometry. Following the
conjugation of Cy3-ESTA, the mean fluorescent intensity of MSV increased
approximately 100 times (from 101 to 10561 AU) (Fig. 41A). To determine the
average amount of ESTA on the MSV, Cy-3 fluorescence was measured using a
fluorimeter. A linear standard curve was generated from Cy-3 ESTA
fluorescence and based on Cy-3 fluorescence from ESTA-MSV, it was
calculated that approximately 106 ESTA molecules were conjugated to each
MSV (Fig. 41B). Together, these data support ESTA conjugation to MSV.
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To further validate the conjugation, the infrared spectrum of ESTA-MSV
was analyzed by Fourier transform infrared spectroscopy (FTIR). FTIR spectra
of ESTA-MSV exhibited an appearance of two distinct peaks (1060 cm-1 and
1651 cm-1) that corresponds to the phospho-linkage (P=O) in DNA and carboxyl
(C=O) chains in the ESTA, respectively (Fig. 41C).
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Figure 40. Conjugation of ESTA-1 to MSV. (A) Schematic of conjugation
chemistry adopted for the conjugation of Cy3-COOH-ESTA to amine modified
MSVs; (B) Fluorescent images of ESTA-MSV. Red – Cy-3 label on ESTA.
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Figure 41. Physico-chemical characteristics of ESTA-MSV (A) Flow
cytometry data of amine modified MSV (blue) and ESTA-MSV (red). (B) Linear
standard curve of the change in fluorescence intensity corresponding to the
number of ESTA-MSV. (C) FTIR spectra of MSV (red), ESTA (blue), ESTA-MSV
(green). Arrows point to the stretching due to P=O and C=O linkages.
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3.3.2 Serum stability of ESTA-MSV
For potential in vivo applications, the serum stability of ESTA-MSV was
evaluated under physiological conditions. ESTA-MSV (106) was incubated in
freshly isolated mouse serum at 37 ˚C up to 5 hours and three different
parameters including MSV stability, ESTA-stability, and stability of ESTA
conjugation on the MSV were analyzed.
•

The size distribution of ESTA-MSV remained unchanged after serum
incubation as measured by dynamic light scattering, which indicated MSV
stability in the serum.

•

Next, stability of ESTA was assessed by serum incubation up to 24 hours
at 37 ˚C followed by gel electrophoresis of the DNA. ESTA-1 was stable
upto 16 hours in the serum, which is consistent with earlier reports that
the thio-substitution enhances serum stability (Fig. 42A).

•

Lastly, to confirm the serum stability of ESTA conjugation to MSV,
intensity of Cy-3 fluorescence from ESTA-MSV was measured at different
time points. There were no changes in the fluorescence intensity after the
5-hour incubation of MSV in the serum (Fig. 42B). The 5 hour time point
was chosen based on the fact that 5 hour is the optimum time required to
achieve in vivo targeting of the MSVs.
We also observed that serum incubation of the negatively charged ESTA-

MSV caused a neutralization of the surface charge of the particles from -35mV
to -15mV due to opsonization. These findings suggest that ESTA-MSV is stable
for up to 5 hours under physiological conditions.
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Figure 42: Stability of ESTA-MSV under physiological conditions. (A) Gel
electrophoresis and densitometric analysis of ESTA-1 after serum incubation for
indicated time points. (B) Quantification of Cy3 fluorescence from ESTA-MSV
after incubation in fetal bovine serum at 37 °C for indicated time points.
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3.3.3 Adhesion of ESTA-MSV to E-selectin expressing endothelial cells
Using E-selectin inducible human microvascular endothelial cell line (ESEndo) (95), we next examined the specific interaction of ESTA-MSV to
endothelial cells expressing E-selectin on the membrane. ES-Endo showed
minimal basal expression of E-selectin and the expression was induced on
treatment with doxycycline (Fig. 43). To test the E-selectin specific binding of
ESTA-MSV, 104 ESTA-MSV was incubated with ES-Endo in the presence of
doxycycline at 4 °C. The number of MSV adhesion to the endothelial cell surface
was three-fold more than MSV alone or to untreated cells (Fig. 43). There was
no significant difference in the number of MSV and ESTA-MSV that are attached
on the endothelial cell surface when E-selectin expression was not induced.
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Figure 43. E-selectin dependent ESTA-MSV adhesion to endothelial cells.
ES-Endo cells were induced with doxycycline for 5 hours to induce E-selectin
expression. The cells were then incubated with ESTA-MSV for 1 hour at 4° C
and then washed and fixed in paraformaldehyde. The number of MSV was
counted in five different fields of view using a microscope and plotted per region
of interest (ROI). Error bars mean ± SEM.
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3.3.4 Development of ESTA-MSV loaded with nanoparticles
Next, the ability of nanoparticle loading to the ESTA-MSV was tested
using three different types of nanoparticles. First, loading of amino (PEG)
quantum dots-655 of (mean diameter = 20 nm) showed a similar overlay pattern
of green (Qdot) and red fluorescence (Cy-3 ESTA) (Fig. 44A top panel).
Similarly, cationic DOPC liposomes containing Oregon green paclitaxel (size
ranging from 25-35 nm) were loaded into the ESTA-MSV (96). The loading of
liposomes was visualized by confocal microscopy by analyzing the overlay of
green (liposomes) and red fluorescence (Cy-3 ESTA)(Fig. 44A bottom panel).
The fluorescence measurements by flow cytometer verified a significant increase
(approximately 100 fold) in red fluorescence after ESTA conjugation to MSV
(ESTA-MSV) and green fluorescence after loading of with Q-dot 655 into ESTAMSV (Fig. 44B). Lastly, the loading of amine functionalized iron oxide
nanoparticles (diameter =15 nm) was also confirmed by Prussian blue staining
(Fig. 44C), and the iron content was quantified to 5 !g of Fe in 107 ESTA-MSV.
These experiments demonstrated the ability of loading nanoparticles, which
could either be a drug carrier (such as liposomes) or an imaging agent (Q-dot or
FeO NPs), into the mesoporous structure of ESTA-MSV.
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Figure 44. Nanoparticle loading into ESTA-MSV. (A) Qdot 655 were loaded
into ESTA-MSV (top panel) Red, Cy-3 ESTA-MSV; Green, Qdot. Ptx
encapsulating DOPC liposomes were loaded into ESTA-MSV (bottom panel)
Red, Cy-3 ESTA-MSV; Green, Oregon green Ptx encapsulated liposomes. (B)
Flow cytometry was carried out to analyze the fluorescence from the surface of
MSV. Red fluorescence measured for ESTA-MSV after conjugation (top panel);
green fluorescence measured for ESTA-MSV before and after loading with Qdot
(bottom panel). (C) Iron oxide nanoparticles were loaded into ESTA-MSV and
amount of iron loaded was measured using Prussian blue analysis. Error bars
mean ± SEM.
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3.3.5 BM targeting of ESTA-MSV
For bio-distribution studies of ESTA-MSV, the mice were intravenously
injected with 5 x107 ESTA-MSV and all major organs including liver, spleen,
heart, lung, bone marrow were harvested after 5 hours and the silicon content
was analyzed using ICP-OES. The accumulation of ESTA-MSV in the bone
marrow was 8 times higher as compared to un-conjugated MSV. The
accumulation of ESTA-MSV in the bone corresponded to over 20 % of injected
dose/g organ weight (P<0.04)(Fig. 45A). The non-targeted MSV exhibited
minimum accumulation in the BM and primarily accumulated in the liver and
spleen. Histological analysis also supported the presence of ESTA-MSV in the
endothelial wall of the BM tissue (Fig. 45B).
Lastly, the delivery of MSV loaded with nanoliposomes containing Oregon
green paclitaxel to the bone marrow was analyzed. Following intravenously
injection, the fresh bone marrow was isolated and analyzed by fluorescent
microscope. A significant accumulation of green fluorescence was observed in
the BM when the liposome loaded ESTA-MSV was injected intravenously. In
contrast, injection of non-targeted MSV loaded with equivalent amount of
liposomes or with naked liposomal only showed minimal accumulation of green
fluorescence in the BM (Fig. 45C).
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Figure 45. In vivo distribution of ESTA-MSV in mice. ESTA-MSV was
injected to mice via tail vein and were harvested 5 hours after the injection and
analyzed for silicon content. (A) Biodistribution of ESTA-MSV represented as
percentage of injected silicon per gram weight of organ. Error bars mean ± SEM.
*P<0.04. (B) Paraffin sections of bone were prepared to visualize the localization
of ESTA-MSV in the bone marrow. (C) ESTA- MSV containing paclitaxel
liposomes were injected in mice and bone marrow tissue was isolated and
stained with DAPI to assess distribution of liposomes. Green, Oregon green
encapsulated liposome; blue, Hoechst 33342.
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Chapter 4. Discussion
Bone marrow is a highly heterogeneous organ performing a critical
function of hematopoieisis and comprising of a wide variety of cell types. Multiple
diseases that originate or involve this organ are associated with a specific cell
type in the BM. Due to this complexity of BM composition and the presence of
healthy hematopoietic progenitor cells, conventional forms of treatment options
are not efficient. Therefore, non-conventional forms of drug delivery are urgently
needed to efficiently deliver therapeutics to the diseased cell type in the bone
marrow
To achieve this goal we proposed a strategy to actively target
therapeutics through targeting of a drug carrier to the bone marrow. For
successfully targeting a drug carrier to a specific site in the body we first
identified three prerequisites.
1. A unique biological target specific to site of delivery
2. A high-affinity ligand against the target molecule
3. An optimally designed drug delivery carrier
In our study we focused on active vascular targeting to achieve an
efficient method of drug delivery. E-selectin a cell adhesion molecule on
endothelial cells was selected as the biological target for active targeting due to
its constitutive expression on BM endothelium and that E-selectin expressed on
the luminal surface of vascular endothelium is readily accessible to systemically
injected drug carriers.
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For targeting E-selectin, although various ligands have been developed
and used for active targeting of nanoparticles to E-selectin expressing cells [4,5],
the usage of these ligands remains a challenge due to low affinity and lack of
serum stability. For example, E-selectin peptide is an L-amino acid peptide that
suffers from bioavailability and stability issues for clinical applications [6]. In fact,
we conducted targeting experiments with MSVs conjugated with high affinity Eselectin peptide and observed that the serum stability of the peptide
compromised the in vivo targeting efficacy. For other ligands such as antibodies,
difficulty in controlling the orientation during chemical conjugation posed a
limitation for targeted delivery. Lastly, due to the structural homology between
different members of the selectin cell adhesion family, isolation of E-selectin
specific selectin ligands has remained elusive. In fact, most of the carbohydrate
mimetic ligands identified for E-selectin exhibit considerable cross reactivity
against other selectins (L- and P- selectin) [7], limiting their use of such for
targeted delivery due to possible off targeting effects. These limitations prompted
me to identify a novel thioaptamer ligand against E-selectin.
Aptamer screening typically consists of binding reactions of combinatorial
libraries with recombinant protein (25-28). However, mammalian proteins
undergo structural differences associated with post-translational modifications,
which cannot be completely mimicked by recombinant proteins. Therefore,
screening with protein alone can lead to identification of aptamers that would not
maintain their binding capabilities to the target protein in a physiological
environment such as in the cells. Hence, the integration of biologically relevant
conditions during the aptamer screening process is crucial for identifying
aptamers that maintain binding under physiologically conditions. Therefore, for
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the identification of E-selectin specific thioaptamer, we utilized a two-step
selection strategy. The first screening step involved screening the combinatorial
library using human E-selectin recombinant protein. Ten iterative cycles of
binding and enrichment of thioaptamers bound to E-selectin protein led to the
identification of 14 TA sequences (Fig. 24). The second step was the cell-based
selection of these 14 candidates using an E-selectin inducible endothelial cells.
Commonly used approaches including induction by cytokines such as TNF-!, IL1" were not employed in this step as they result in induction of a wide variety of
surface molecules and it would be difficult to rule out the involvement of these
other cell surface molecules during the E-selectin specific screening of
thioaptamers. Therefore, we developed a doxycycline inducible E-selectin
expression endothelial cell line for a controllable and highly selective induction of
E-selectin expression. In the cell-based selection, only one of the 14 selected
TA’s exhibited highly doxycycline-dependent binding to endothelial cell
expressing E-selectin (Table 2). This was surprising because the initial TA
screening was conducted using human recombinant E-selectin protein isolated
from the mammalian system. This points out the fact that the first step of
screening of TA’s from the combinatorial library yielded ligands of relatively high
affinity, but low specificity (less doxycycline-dependent binding) to the E-selectin
expressing cells.
Most mammalian proteins undergo structural changes associated with
post-translational modifications, which cannot be completely mimicked by
recombinant proteins. Therefore, in vitro ligand selection with pure biochemical
entities (e.g., recombinant protein) may not mimic effective ligand binding in a
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complex biological environment, particularly if the target protein is significantly
post-translationally modified such as in the case of E-selectin. E-selectin protein
undergoes sequential post-translational modification and is matured from 51 kDa
to 115 kDa. Thus, the integration of 2nd step of biologically selection in the
screening process is essential for the identification of highly specific and high
affinity ligands. Overall, the two-step screening strategy allowed us to identify a
novel E-selectin thioaptamer (ESTA-1) that specifically binds to E-selectin
expressing on the endothelial cell surface (Fig. 31). Our data demonstrated that
mono-thiophosphate substitution in ESTA-1 resulted in high affinity binding to Eselectin (47 nM) (Fig. 35). This is a significant improvement of 2,000-40,000
times higher affinity as compared to the natural ligand sLex (KD= 100–2000 mM)
(13). Also the sulfur substitution of the phosphate oxygens on the DNA
backbone in ESTA offers enhanced serum stability. Moreover, dithio-substituted
DNA has been shown to increase the binding affinity of non-thioated or monothio
analogue by 100–600 times [30]. This suggests that dithio-substitution of ESTA1 can lead to further development of higher affinity of ligands against E-selectin.
Additionally, we demonstrated that the ESTA-1 binds E-selectin with negligible
cross reactivity to L- and P-selectin (!M). Minimal cross reactivity of ESTA-1
further highlights the potential utility of ESTA-1 for highly selective E-selectin
targeted therapeutic and imaging applications. Lastly, we tested ESTA-1 binding
to E-selectin expressing vessels in both human carcinoma pathology samples
and animal models to ensure that ESTA-1 bound E-selectin independent of
species differences. We believe that sequence and structural homology between
human and mouse E-selectin [8] resulted in species independent binding of
ESTA-1 to E-selectin. In addition, ESTA-1 is stable under physiological
%&'!
!

conditions for up to 16 hours (Fig. 42). This fact makes ESTA-1 extremely useful
for pre-clinical validation and for possible clinical applications. Furthermore,
ESTA-1 effectively inhibited the E-selectin dependent adhesion of leukocytes on
endothelial cells (Fig. 39). Therefore, ESTA-1 can also be utilized as an
antagonist to block the E-selectin dependent leukocyte recruitment cascade
during chronic inflammation.
One of the foremost applications of ESTA-1 is for targeted delivery of
drug carriers to E-selectin as described in this study. We utilized the multistage
drug delivery strategy, which has been developed by our group. This strategy is
based on circumnavigating biological barriers present in the body by
incorporating multiple stages thereby maximizing site-specific localization and
release of therapeutics therein. The first stage comprises of porous silicon
microparticles as drug carriers and involves encapsulating drug-containing
nanoparticles within MSVs that protect and ferry these nanoparticles until they
recognize and dock at their target site on the vasculature. Using an integrated
approach combining in silico mathematical modeling with in vitro and in vivo
experiments, MSVs were rationally designed with a hemispherical geometry to
maximize localization and adhesion to vasculature, whilst minimizing RES
uptake [9]/! Porous silicon was chosen because it is highly biodegradable into
harmless silicic acid byproducts under physiological conditions, presenting fewer
challenges for long-term use and has received FDA approval. The degradation
kinetics of MSVs is dependent on the pore characteristics, which can be tailored
during their fabrication. Since the release of nanoparticle payload is dependent
on the degradation of MSV, the release can be tightly regulated. One of the
applications of MSV can be to function as intravascular depots, whereby MSVs
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are fabricated to undergo slow degradation leading to a sustained release of
therapeutic payload. This property was successfully demonstrated for the
sustained delivery of siRNA-encapsulated liposomes incorporated into the MSV
to achieve sustained gene silencing in ovarian tumors. The silencing of Epha2
gene in ovarian tumor by a single intravenous injection of MSV loaded with
Epha2 siRNA liposomes lasted three weeks, which was comparable to six
repeated injections of siRNA liposomes alone (Fig. 20). In addition, our data
indicated that MSV-loaded liposomal siRNA reduced the induction of
inflammatory cytokines as associated with liposomes alone (Fig. 22). This
silencing led to significant tumor shrinkage and therapeutic efficacy in animals
bearing ovarian xenografts (96).
The fact that BM exhibits unique vascular characteristics, for instance the
average hydrodynamic shear rate in the BM microvessels being lower than in
other organs [10], higher margination and subsequent adhesion to the vessel
wall is expected. This vessel binding can be further enhanced by the presence of
high affinity targeting ligands [11]. Porous silicon offers ease of surface
modifications for chemical conjugation of targeting ligands. ESTA-1 was
conjugated to MSV and confirmed by multiple techniques. ESTA-MSV showed
higher adhesion to E-selectin positive endothelial cells in vitro and in vivo. ESTAMSV showed enhanced localization in the BM tissue (20 % injected dose/g
organ) and significantly enhanced delivery of therapeutic liposomes incorporate
in the porous structure of MSVs (Fig. 45). Comparing these results with an
earlier study by Tari et al, we estimated that 200 times more liposomes could be
delivered to the BM tissue carried by the ESTA-MSV as compared to an injection
of equivalent amount of liposome alone [12]. The targeting experiments in this
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study have been conducted in disease free animals, and as mentioned earlier
certain pathological and physiological stimuli can cause changes in the vascular
characteristics of BM. Therefore it still remains to be evaluated how such
changes would affect the MSV targeting to the BM vasculature.
One of the unique advantages of MSV is the flexible choice of payload
such as lipid-based carriers, metal nanoparticles or drug alone that can be
loaded into the porous MSVs. As a proof of concept, we demonstrated three
types of nanoparticles loaded into the porous structure of ESTA-MSV (Fig. 44).
Based on our calculations, 7x104 iron oxide nanoparticles (with a 15 nm
diameter) were incorporated into the pores of a single ESTA-MSV (1.6 µm
diameter, 60 % porosity). As described by a recent study from our group, the
geometrical confinement of iron oxide nanoparticles in the MSV can lead to
enhancement of contrast for imaging applications (104). Therefore, delivery of
MSV loaded with such iron oxide nanoparticles can have imaging applications.
The advantage afforded by this multistage approach for drug delivery are
easily appreciable, and lie in its multi-functionality and its ability to favorably alter
the pharmacokinetics of drugs. A combination of two biocompatible materials
(MSV and ESTA), may allow for wide ranging applications such as described
below:
1. Treatment of pathological conditions associated with bone marrow [11].
2. For non-invasive methods of diagnostic imaging for the evaluation of
multiple clinical problems for
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• determining the amount of active marrow after X-irradiation and
chemotherapy
• diagnosis and detection of metastases
• location of the sites for marrow biopsy
3. Delivery of agents for the suppression of the inherent function of the bone
marrow. This can be particularly effective in preventing rejection following
organ

transplantation.

Currently

used

immunosuppressant

such

as

Cyclosporin A is associated with significant side effects, particularly
nephrotoxicity, when used for prolonged periods [12].
4. Majority of conventional chemotherapeutic drugs have limitations to the
dose administered due to their toxicity to the bone marrow. Several
hematopoietic growth factors such as CSF-1 and GM-CSF, can mediate selfrenewal, proliferation, maturation and activation of marrow cells [13]. This
class of agents can be delivered to the bone marrow for protection of bone
marrow and stimulation of its hematopoietic function in conjunction with the
chemotherapy.
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4.1 Future work and directions
In this study, we provide first evidence of organ specific active targeting
for delivery of nanoparticles to the BM tissue via E-selectin. This multistage
system can further be improved by loading nanoparticles that can target specific
cell type in the bone marrow space. This can be achieved by conjugating the
nanoparticle with ligands specific to a cell type of interest. Such a two-step active
targeting concept comprising of organ targeting followed by cell targeting can
further improve the efficacy and potentially minimize the effect of drugs on
healthy hematopoietic cells. One example can be the case of breast cancer
bone metastases where cancer cells metastasizing to the bone marrow cause
hypercalcemia and their self-stimulation via a “vicious cycle” through maturation
of osteoclast via activation of cell membrane-associated proteins termed
receptor activator of NF-$B ligand (RANK/RANKL axis). The mature osteoclasts
mediate osteolysis (bone resorption) and also secrete growth factors such as
TGF-# that stimulate tumor growth, leading to pathological hypercalcemia. This
study can be applied to achieve inhibition of this osteoclastogenic vicious cycle
by the delivery of therapeutic agents specifically at the metastatic sites in the
bone marrow without affecting the normal hematopoietic precursor cells. Utilizing
the two-step sequential targeting; first the MSV targets to the bone marrow
metastatic niche via E-selectin, then RANK peptide conjugated nanoparticles
released from MSV in the bone marrow will target osteoclasts. This can
potentially lead to enhanced local delivery of therapeutics to the osteoclast in the
bone marrow metastatic niche and reduce bone resorption without affecting
healthy hematopoietic precursor cells.
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